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Microarray analysis of pathways involved in bladder cancer invasion and 
metastasis 
Abstract (word count =300) 
Hypoxia-inducible genes have been linked to the aggressive phenotype of 
cancer. However, nearly all work on hypoxia-regulated genes has been 
conducted in vitro on cell lines. Here the hypoxia transcriptome in primary 
human bladder cancer was investigated using cIDNA microarrays to compare 
genes induced by hypoxia in vitro in bladder cancer cell line EJ28 with genes 
upregulated on an in vivo array of 39 bladder tumours (27 Ta/T1 12 T2-T4). 
mRNA array fold-changes were correlated with carbonic anhydrase IX (CA IX) 
staining and necrosis of tumours as surrogate markers of hypoxia. Of 6000 
genes 32 were repeatedly hypoxia-inducible in vitro more than 2-fold, five of 
which were novel, including lactate transporter SLC16A3 and RNAse 4. Eight 
of 32 hypoxia-inducible genes in vitro were also upregulated on the vivo array. 
Vascular endothelial growth factor (VEGF) mRNA was upregulated 2-fold by 
hypoxia and 2 to 18-fold in 31/39 turnours. Also up regulated on both arrays 
was GLUT 1 mRNA, and fold changes on the in vivo genearray significantly 
correlated with CA IX staining of tumours (p=0.008). However Insulin-like 
growth factor binding protein 3 (IGFBP-3) mRNA was the most strongly 
differentially expressed gene in both arrays and its upregulation was confirmed 
in the urine of bladder cancer patients (n=157, p<0.01) and in cell line 
supernatants. Angiogenin was also upregulated in urine of bladder cancer 
patients. Selected genes upregulated by hypoxia (HIF la, HIF 2a, CA IX and 
NIP3) were studied by immunohistochernistry for their prognostic significance 
and association with necrosis in 98 cystectomy specimens. Normal human 
urothelial cells were also grown in culture and a hypoxia genearray profile 
compared with EJ28, peripheral blood monocytes and T-cells. This thesis 
studies the prevalence of hypoxia and necrosis in bladder cancer, its 
relationship with prognosis, genes associated with the hypoxic phenotype and 
hypoxia related molecular pathways. 
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1.1 Bladder Cancer, epidemiology, screening, clinical presentation, risk of 
recurrence and progression to invasion of muscularis propria. 
Bladder cancer is the fourth commonest cancer in men, with an incidence of 
30/100,000 in England and Wales in 1998,11,500 new cases and 4,500 deaths 
in the U. K. per annum. A quarter of all cases are in women in whom the 
incidence is 10/100,000. Non-invasive bladder cancer is managed by 
endoscopic resection, intravesical chemotherapy and surveillance cystoscopy 
for a period of at least 10 years. Up to a half of all non-invasive bladder cancers 
progress and a quarter of all bladder cancers present with disease invading into 
the muscularis propria of the bladder (muscle invasive bladder cancer). The 5- 
year survival rate of muscle invasive disease with radical treatment is 50%. 4% 
of all cancer deaths in England and Wales are due to bladder cancer. The 
incidence of bladder cancer increases directly with age, with median age at 
diagnosis 69 years in men and 71 in women (Lynch and Cohen 1995). 
Metastases occur to lymph glands, liver, lung, bone, intestine and adrenals (in 
order of frequency). Patients who develop metastasis do so at a mean of 11 
months from diagnosis (Babaian, Johnson et al. 1980) making it a fast growing 
cancer. Unlike prostate cancer, thyroid cancer or even lung cancer, bladder 
cancer is not reported to be found as a latent cancer at autopsy (Imaida, 
Hasegawa et al. 1997). Multifocal and recurrent tumours have been shown to 
have a monoclonal origin (Chern, Becich et al. 1996) but a recent review of the 
evidence suggests an oligoclonal origin to bladder cancer (Duggan, Gray et al. 
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2004). Clonality assays of muscle-invasive bladder cancer have repeatedly 
shown that there is evidence for subclonal evolution. That is, all turnours, shared 
some genetic events but there were many accumulated differences, indicating a 
great overall genetic instability (Anderson 2005). Case reports of familial 
transitional cell carcinoma have been described with a variety of genetic defects 
described (Kiemeney and Schoenberg 1996). There have been few 
epidemiological studies, one suggesting an increased risk of 2-fold for first 
degree relatives, but another in the founder population of Iceland argued against 
a hereditary subtype of bladder transitional cell carcinoma, at least in that 
population (Kiemeney, Moret et al. 1997). The only known associated clinical 
syndrome associated with transitional cell carcinoma is hereditary nonpolyposis 
colon cancer, which increases the risk of upper tract tumours but not bladder 
turnours by 10-fold (Watson and Lynch 1993). 
The most common presenting symptom of bladder cancer is painless 
haernaturia, which occurs in about 85% of patients (Varkarakis, Gaeta et al. 
1974). In reality nearly all patients with cystoscopically detectable bladder 
cancer have at least microscopic haernaturia if enough urine samples are taken. 
Most commentators agree that there is no value in screening the general 
population because the incidence of bladder cancer in those under the age of 40 
is so low and the incidence of microscopic haematuria in this group may be as 
high as 5.4% (Tomson and Porter 2002) . However a case 
has been made for 
screening selected high-risk groups such as older men. In one large study 
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(n=1 340) with repeated urine testing in men over 50 years of age the prevalence 
of microscopic haernaturia was 21 %(Messing, Young et al. 1992). Urothelial 
cancer was found in 8% of this group (or 1.2% of those screened). Screening for 
bladder turnours in this way can pick them up at a significantly earlier stage with 
a benefit to prognosis (Messing, Young et al. 1995). However screening would 
have to be completed at least annually (Messing, Young et al. 1995), and there 
has never been a randomised trial of such a screening programme. Furthermore 
given the proportion of bladder cancer cases attributable to smoking is at least 
one third (Burch, Rohan et al. 1989) (Howe, Burch et al. 1980) any money spent 
on bladder cancer might be better spent on primary prevention rather than 
screening. 
Sylvester has published tables that allow urologists to easily calculate a 
superficial bladder cancer patient's short- and long-term risks of recurrence and 
progression after transurethral resection. An analysis was carried out of 
individual patient data from 2596 superficial bladder cancer patients included in 
seven European Organization for Research and Treatment of Cancer trials. A 
simple scoring system was derived based on six clinical and pathological 
factors: number of tumors, tumor size, prior recurrence rate, T category, 
carcinoma in situ, and grade. The probabilities of recurrence and progression at 
one year ranged from 15% to 61 % and from less than 1% to 17%, respectively. 
At five years, the probabilities of recurrence and progression ranged from 31% 
to 78% and from less than 1% to 45%. With these probability tables, the 
urologist can discuss the different options with the patient to determine the most 
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appropriate treatment and frequency of follow-up. (Sylvester, van der Meijden et 
al. 2006) 
(see table below taken from Sylvester) 
Table 3: Weighting used to calculate recurrence and progression scores 
Factor Recurrence Progres5lon 
ý-, Lmb-ar of Tumours 
Single 0 0 
2 to 7 3 3 
-. 8 
Tumcur Diameter 
<3 cm 0 
13 Cm 3 3 
Prior Recurrence Rate 
P, irnary 0 0 
I recurreme/year 2 2 
1 recurrenc--s-, 'year 4 2 
Category 





G, ade (1973 WHO) 
Gi 0 
G2 0 
C-3 2 5 
Total Score 0-17 0-23 
CIS orna I OU. Mc-IW = r8clllrl9rý" PO' 
Table 4: Probability of recurrence and progression according to score 
Recurrence sco-re Probability of recurrence Probability of recurrence 
at I year (9-504 Cl) at 5 years (95% Cl) 
15 113 1 31 ý-, d (24 1! 1ý6.3 7 
14 J-4 4 (21%. 26, -: jýl 461- f 2%. 49-: ý:, ) 
ý-g 
10-17 611,10 (55 67 784 (735,3 , 84 
Progression score Probability of progression Probability of progression 
at I year (95% Cl) at 5 years (951% Cl) 
0,21 '!. -u (0 0.7,,!.,,, 08 (0 111ý. 1,7 
2-6 1c. C (0,4141,1-6-ý; j 6' (5c, , 
i; c 
7-13 6 (14 1!. 20 
17 9129,45% (35%, 55%) 14-ý 
141 
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1.2 Hypoxia is common in solid cancers and is a major cause of radio and 
chemoresistance 
Hypoxia is a common feature of solid human tumours (Vaupel, Kallinowski et al. 
1989). Tissue oxygen levels in human tumours have been measured with 
eppendorf electrodes since 1984. The tumours measured by this technique 
include sarcomas, cervix, prostate, and head and neck tumours (Brizel, Scully et 
al. 1996; Hockel, Schlenger et al. 1996; Becker, Hansgen et al. 1998; Movsas, 
Chapman et al. 1999; Movsas, Chapman et al. 2001). A significant proportion of 
these turnours have median oxygen tensions below 10mm Hg. In these same 
studies it was shown that neighbouring muscle (periprostatic (Movsas, 
Chapman et al. 1999) or sternocleidomastoid (Becker, Hansgen et al. 1998)) 
and normal tissue (prostate (Movsas, Chapman et al. 1999)) had comparatively 
higher tissue levels of oxygen. End-capillary (mixed venous) oxygen tension is 
40mm Hg (75% saturation), and a reasonable estimate of mean resting tissue 
p02 is 10mmHg (Berne and Levy 1996). Hypoxic tumours are usually defined 
as having a median p02 of <10mmHg. 
Xenograft experiments measuring oxygenation with eppendorf electrodes in 
turnours at different stages of growth suggest that although smaller turnours 
may vary in their proportion of hypoxic cells, larger tumours (above only 2g) are 
universally hypoxic (De Jaeger, Merlo et al. 1998). Seminal observations by 
L. H. Gray 50 years ago (Thomlinson and Gray 1955) on human lung cancer 
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suggested that cancer cells grow in cords around blood vessels. Gray analysed 
160 turnours and with only one exception no intact tumour cell was seen more 
than 180ýtfrorn the stroma, and there was no tumour cord more than 200[t in 
radius that was not without central necrosis. Regions of necrosis are believed to 
demarcate regions of severe, 'chronic' hypoxia. Gray's observations and 
experiments suggest that very early on in tumour development, tumour cells 
receive inadequate perfusion for their needs and areas of hypoxia and necrosis 
can develop even in small tumours. Another type of hypoxia known as acute 
hypoxia occurs when aberrant blood vessels are shut down. Closed vessels can 
be reopened leading to reperfusion of hypoxic tissues with oxygenated blood, 
leading to reperfusion injury. 
Eppenclorf measurements have shown tumour hypoxia to be independently 
related to prognosis, being associated with aggressive local growth, metastasis, 
and treatment failure (Brizel, Scully et al. 1996; Hockel, Schlenger et al. 1996; 
Nordsmark and Overgaard 2000). Pelvic recurrences of cervical cancer are 
significantly more hypoxic than the primary tumour (Hockel, Schlenger et al. 
1998). 
The impact of oxygen on radiosensitivity of mammalian tumours was 
demonstrated as early as the 1950s when Gray et al (Gray, Conger et al. 1953) 
published their seminal treatise on oxygen and radiation. The summary of the in 
vitro experiments is shown (Fig 1.1). As oxygen levels fall from 21%, 
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radiosensitivity falls in all in vitro experimental systems tested including; growth 
rate of vivia faba root tips, lethal mutations in drosophila melanogaster, and 
cytological damage to mouse ascites tumour cells. Gray's paper describes a 
large in vivo experiment on 124 mice with the Ehrlich mouse ascites tumour. 
The mouse tumours were exposed to 1000 rad x-rays in air, or 1000 rad in pure 
oxygen, or 1500 rad or 2000 rad in air. Breathing pure oxygen critically 
increased radiosensitivity of the tumours to the equivalent of an extra 500 rad 
Interestingly Gray also observed in this paper that tumours that had been 
allowed to grow for 9 days or longer, the effectiveness of extra inhaled oxygen 
was only very slight. Gray hypothesised that in larger tumours the capillary 
structure may be such that when the animal breathes oxygen there are regions 
of turnour tissue in which the oxygen tension is not significantly raised. Gray 
also proposed the correct mechanism that the role of dissolved oxygen is to 












FiG. 1 B. 
Typical curve of radiosensitivity as a function of oxygen 
tension at the time of irradiation. 
Absciss(ie: (), tension at the time of irradiation. 
Ordiii(ites: Radjosensitivity. 
Fig 1.1 Summary of the findings of the in vitro experiments of oxygen on 
radiosensitivity. (Gray, Conger et al. 1953) 
Trials of hyperbaric oxygen as a sensitizer for radiotherapy in the 1970s were 
positive for head and neck and cervical carcinomas but not for bladder tumours 
(1978). In bladder cancer there may be areas where oxygen tension is not 
significantly raised. Encouragingly subsequent trials of the use of 95% oxygen 
in the form of inhaled carbogen have shown a positive radiosensitising effect in 
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bladder cancer (Hoskin, Saunders et al. 1999) and Phase III trials are now 
starting in the UK(Hoskin, Rojas et al. 2005). 
Long-term follow-up of radical radiotherapy failures in the treatment of invasive 
bladder cancer has consistently shown that T stage (T2/T3a vs T3b/T4) and 
tumour bulk are the main factors affecting survival (Gospodarowicz, Rider et al. 
1991). One of the aims of this thesis was to accurately measure the proportion 
of cancers with necrosis at each stage to see if this might be a likely factor in 
radioresistance.. 
Hypoxia also affects chemotherapeutic agents adversely by leading to growth 
arrest, which makes the cells less amenable to cytotoxic effects. Hypoxia also 
induces the multidrug resistance gene 1 (Comerford, Wallace et al. 2002) 
among other stress response genes. However hypoxia within cells can also be 
used to an advantage. The agent mitomycin, which is current standard of 
treatment given intravesically to all patients as a one off dose immediately after 
superficial bladder tumour resection is known to be activated preferentially in 
hypoxic cells. As will be seen later the luminal surface of superficial bladder 
cancers is hypoxic and so intravesical installation of this agent is the ideal route. 
Levels of two reductase enzymes upregulated in hypoxic cells are known to 
correlate with mitomycin activity (Gan, Mo et al. 2001). The corresponding 
down-regulation of these enzymes in more aggressive tumours contributes to 
mitomycin resistance (Baumann, Hodnick et al. 2001). 
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1.3 The HIF 1 pathway 
One of the ways in which cells respond to reduced oxygen levels is through 
hypoxia-inducible transcription factor 1 (HIF-1)(Harris 2002; Semenza 2003). 
HIF-1 is a heterodimer that consists of the hypoxic response subunit HIF-la 
and the constitutively expressed protein HIF-1p subunit. As for any protein, the 
level of HIF-1a expression is determined by the rates of protein synthesis and 
protein degradation. In the case of HIF-la, synthesis is regulated by 02- 
independent mechanisms (Fig 1.3), whereas degradation is regulated primarily 
via02-dependent mechanisms (Fig 1.4). In the presence of oxygen, the prolyl 
hydroxylase enzymes (1-3) hydroxylate HIF-laat proline residues 402 and 
564. This allows the Von Hippel-Linclau (VHL) protein to bind HIF-Ia labelling it 
for proteosome degradation. VHL binding is also promoted by acetylation of 
lysine (K) residue 532 by the ARD1 acetyltra nsfe rase. 02-dependent 
hydroxylation of asparagine (N) residue 803 by the enzyme FIH-1 (factor 
inhibiting HIF-11) blocks the binding of the transcriptional complex (p300 and 
CBP) to HIF-1a and therefore also inhibits HIF-let mediated gene transcription 
(although more recent references show this is not confirmed. ). In hypoxic 
conditions the prolyl and asparagines residues are not hydroxylated and HIF-la 
consequently is not degraded and is able to proceed with transcription. 
An additional complicating factor is the existence of the related protein HIF-2cc, 
which can also dimerise with HIF-1P. Initially a specific role in endothelium was 
suggested for HIF-2a however experiments in control and hypoxic rats showed 
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that HIF-2a was not detectable under baseline conditions, and marked hypoxic 
induction occurred in all organs investigated. In some organs induction of HIF- 
2a was exclusively nonparenchymal (kidney) but predominantly parenchymal in 
others (liver and intestine). Fitting with this result, experiments with small 
interfering RNAs have shown that hypoxia induction of three known hypoxia- 
inducible genes (CA IX, GLUT-1 and BNIP3) was found to be critically 
dependent on HIF-2cc in renal cancer cell lines but not in other cell lines tested 
which where HIF-1a dependent (Sowter, Raval et al. 2003). Furthermore down 
regulation of HIF-2cc may be sufficient to suppress tumour formation by pVHL- 
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Fig 1.3 Oxygen-independent regulation of HIF-1a synthesis. Growth factor 
binding to a cognate receptor tyrosine kinase activates the phosphatidylinositol 
3-kinase (Pl3K) and mitogen-activated protein kinase (MAPK) pathways. P13- 
Kinase and RAS activate downstream pathways that increase the rate at which 
a subset of mRNAs within the cell are translated into protein. (Semenza 2003) 
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Oxygen-independent regulation of HIF-1 differs from oxygen-dependent 
regulation in two respects. First, as already mentioned, growth factors, 
cytokines and other signaling molecules stimulate HIF-1a synthesis rather than 
degradation. Second, whereas hypoxia increases HIF-la levels in all cell types, 
growth-factor stimulation induces HIF-1cc expression in a cell-type-specific 
manner via activation of phosphatidylinositol kinase (P13K) or mitogen activated 
protein kinase (MAPK) pathways. Of course these pathways are not specific to 
HIF-1a and also affect the translation of dozens of different mRNAs. HIF-1a 
protein is likely to be particularly sensitive to changes in the rate of synthesis 
because of its extremely short half-life under non-hypoxic conditions. This link 
between growth factors and HIF-1 is probably of functional and evolutionary 
importance. Proliferation of cells increases oxygen consumption in a given 
microenvironment. As one cell produces two daughter cells, 02 consumption 
increases. It is not surprising therefore that the main pathways that transduce 
proliferative and survival signals from growth-factor receptors also induce HIF- 
la expression. This can be viewed as a preemptive strategy for maintaining 
oxygen homeostasis. In addition proliferating cells preferentially use glycolytic 
rather than oxidative metabolism to generate ATP. The induction of glycolysis in 
proliferating cells is mediated partly by activating HIF-1 (see Glycolysis). This is 
demonstrated by the coordinated upregulation of HIF-1a with proliferation of 
migrating basal keratinocytes seen in normal wound healing in humans (Elson, 
Ryan et al. 2000). 
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1.4 The function of HIF-1 
HIF-1a knockout mice die in utero on day El 1 (Kotch, lyer et al. 1999). Although 
vascular malformations are evident, the principle cause of cell death is thought 
to be mesenchyrnal because cell death precedes vascular malformation. This 
suggests a primary role of HIF-1 in the survival of cells. In these embryos VEGF 
(Vascular Endothelial Growth Factor) was surprisingly not deficient. HIF-1cc is 
not essential for VEGF production. 
Xenografted HIF-1cc or HIF-1p knockout cancerous cells have a slower rate of 
tumour growth ((Jiang, Agani et al. 1997; Maxwell, Dachs et al. 1997; Ryan, Lo 
et al. 1998; Ryan, Poloni et al. 2000)) (except in (Carmeliet, Dor et al. 1998)) 
while cells with increased HIF-1a activity have an increased rate of growth 
((Ravi, Mookerjee et al. 2000; Akakura, Kobayashi et al. 2001; Maranchie, 
Vasselli et al. 2002)). One experiment suggested that HIF-1a knockout cells 
become necrotic in poorly vascularised areas but grow well in vascularised 
areas (Blouw, Song et al. 2003), which would support the hypothesis that HIF- 
Ict acts as a survival factor in areas of hypoxia. 
Further evidence supporting this hypothesis comes from tissue-specific 
knockout mice. The advantage of such mice is that they survive the early 
developmental death of the global knockout. Tissue-specific targeting to delete 
HIF-Icc in an avascular tissue; the cartilaginous growth plate of developing bone 
shows that cells that lack HIF-1a in the hypoxic interior of the growth 
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plate die (Schipani, Ryan et al. 2001). Tissue specific knockouts of HIF-1a in 
monocytes and macrophages of the myeloid lineage demonstrated dramatically 
that HIF-1a is essential for regulation of glycolytic capacity: When HIF-1(x is 
absent, the cellular ATP pool is drastically reduced, the metabolic defect results 
in profound impairment of myeloid cell function resulting in experimental skin 
wounds having no inflammatory component to their healing compared to 
controls (Cramer, Yamanishi et al. 2003). 
1.5 HIF-la and human cancers 
Immunohistochernical analysis using monoclonal antibodies revealed that HIF- 
1(y is over expressed in many human cancers. Although immunohistochernical 
analysis can be useful in determining whether a specific protein is present at 
higher levels in cancer cells compared with surrounding normal tissue, it does 
not reveal whether the protein carries any alterations which could affect its 
function (for example with non-functional p53 protein overexpression). 
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Tumour type Association References 
Cervical, early stage Increased mortality (Birner, Schindl 
et al. 2000) 
Cervical, RXT Increased mortality (Burri, Djonov et 
al. 2003) 
Lung, NSCLC Decreased mortality (Volm and 
Koomagi 2000) 
Lung, NSCLC Increased mortality (HIF-2a) (Giatromanolaki, 
Koukourakis et 
al. 2001) 
Breast, LN-positive Increased mortality (Schindl, 
Schoppmann et 
al. 2002) 
Breast, LN-negative Increased mortality (Bos, van der 
Groep et al. 
2003) 
Oligodendroglioma Increased mortality (Birner, 
Gatterbauer et 
al. 2001) 
Oropharyngeal SCC Increased mortality, radiation (Aebersold, 
resistance Burri et al. 
2001) 
Ovarian Increased mortality (with p53) (Birner, Schindl 
et al. 2001) 
Oesophageal, early Increased mortality resistance to (Koukourakis, 
stage PDT (with BCL2) Giatromanolaki 
et al. 2001) 
Endometrial Increased mortality (Sivridis, 
Giatromanolaki 
et al. 2002) 
Head and Neck SCC Increased mortality (Koukourakis, 
Giatromanolaki 
et al. 2002) 
GI stromal tumour of Increased mortality (Takahashi, 
stomach Tanaka et al. 
2003) 
Table 1.1 Increased HIF-1a levels in human cancers by immunohistochernistry. 
GI, gastrointestinal; LN, lymph node; NSCLC, non-small-cell lung cancer; PDT, 
photodynamic therapy; RTX, radiation therapy; SCC, squamous-cell carcinoma 
(Taken from (Semenza 2003)) 
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At the time of initiating work there were no studies investigating HIF-la in 
bladder cancer. However one group did publish two papers while work was in 
progress (see Chapter 6.3). Significant associations between HIF-la 
overexpression and patient mortality have been shown in cancers of the brain, 
breast, cervix, oropharynx, ovary and uterus (endometrial) (Table 1.1). In some 
cancer subtypes, such as oropharyngeal cancer, the association was observed 
among tumours from all patients, whereas in other cancer types the association 
was observed only in specific subgroups, such as in early-stage cervical cancer. 
By contrast, associations between HIF-la overexpression and decreased 
mortality were reported for patients with head and neck cancer and non-small- 
cell lung cancer although other studies failed to replicate these results. 
The mechanism for this upregulation varies in different cell types and turnours. 
In the VHL syndrome and over 90% of sporadic renal cell carcinomas this is 
characteristically due to VHL loss of function and reduced degradation of HIF- 
Ia. In other tumours increased synthesis from oncogenic and signaling changes 
plays the main part (Table 1.2). 
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Alteration in tumour Mechanism of HIF-la induction Reference 
VHL loss of function Decreased ubiquitylation (Maxwell, 
Wiesener et 
al. 1999) 
P53 loss of function Decreased ubiquitylation (Ravi, 
Mookerjee et 
al. 2000) 
PTEN loss of function Increased synthesis (Zundel, 
Schindler et 
al. 2000) 
P13K-AKT-mTOR Increased synthesis (Laughner, 
signalling Taghavi et al. 
2001) 
MEK-ERK signalling Increased synthesis (Fukuda, 
Hirota et al. 
2002) 
ERB132 gain of function Increased synthesis (Laughner, 
Taghavi et al. 
2001) 
EGFR signalling Increased synthesis (Zhong, 
Chiles et al. 
2000) 
IGF1 R signalling Increased synthesis (Fukuda, 
Hirota et al. 
2002) 
PGE2signalling Increased synthesis (Liu, 
Kirschenbaum 
et al. 2002; 
Fukuda, Kelly 
et al. 2003) 
SRC gain of functon Increased synthesis (Jiang, Agani 
et al. 1997) 
ARF loss of function Decreased nucleolar (Fatyol and 
sequestration Szalay 2001) 
Table 1.2 Genetic alterations that increase HIF-11 activity. Where the alteration 
is due to increased signalling this may be due to genetic alteration in a 
component of the pathway or an upstream activator. For example AKT gain of 
function mutation or PTEN loss-of-function mutation induces P13K-AKT-mTOR 
signalling; EGFR amplification or TGF-cc overexpression induces EGFR (and 
P13K-AKT-mTOR and MEK-ERK) signalling. EGFR, epidermal growth factor 
receptor; ERK, extracellular-signal-regulated kinase; IGFR1, insulin-like growth- 
factor-1 receptor; MEK, MAP/ERK kinase; mTOR, mammalian target of 
rapamycin; PGE2, prostaglandin E2; P13K, phosphatidylinositol-3-kinase; VHL, 
von Hippel-Lindau protein. (Taken from (Semenza 2003)) 35 
1.6.1 HIF-1 target genes and biological responses to hypoxia 
More than 60 putative direct HIF-1 targets have been identified. These can be 
grouped into a variety of biological responses. (Fig 1.5) One of the first targets 
of HIF-1 to be recognized was erythropoietin production in renal cells, which 
increases hemoglobin production. More universally, hypoxic cells undergo a 
shift from aerobic to anaerobic metabolism; they upregulate the enzyme 
carbonic anhydrase IX to regulate pH; they produce growth factors that produce 
angiogenesis (new blood vessel formation); and they produce factors that 
promote invasion and metastasis. All of these biological responses are 
potentially cancer promoting and are discussed below. However hypoxia also 
has been shown to cause cell cycle arrest in response to hypoxia in 
untransformed cells (embryonic murine fibroblasts and splenic B lymphocytes), 
and HIF-1 is a major regulator of cell cycle arrest in this circumstance, 
independent of p53 (Goda, Ryan et al. 2003). Upregulation of p2l and p27 
cyclin-dependent kinase inhibitors is associated with this arrest. HIF-1 also 
upregulates aponecrotic pathways such as BNIP3 and NIX (Sowter, Ratcliffe et 
al. 2001)). Therefore it can be said that presence of HIF-11 signals low oxygen, 
but the biological response of the cell may depend on the developmental, 
physiological and, in the case of cancer, oncogenic environment in which the 
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Fig 1.4 (previous page) Genes that are transcriptionally activated by HIF-1. ADM 
adrenomedullin; AILDA, aldolase A; ALDC, aldolase C; AMF, autocrine motility factor; CATHD, 
cathepsin D; EG-VEGF, endocrine-gland-derived VEGF; ENG, endoglin; ET1, endothelin-1; 
EN01, enolase 1; EPO, erythropoietin; FN1, fibronectin 1; GLUT1, glucose transporter 
1; GLUT3, glucose transporter 3; GAPDH, glyceraldehydes-3-P-dehydrogenase; HK1, 
hexokinase 1; HK2, hexokinase 2; IGF2, insulin-like growth factor 2; IGFBP-1, IGF-factor- 
binding-protein-l; IGFBP-2, IGF-factor binding protein-2; IGFBP-3, IGF-factor binding protein-3; 
KRT14,18,19 keratin 14,18,19; LDHA, Iactate dehydrogenase A; LEP, Ieptin; LRP1, ILDIL-receptor- 
related protein-l; MDR1, multidrug resistance 1; MMP2, matrix metal loproteinase 2; NOS2, nitric 
oxide synthase 2; PFKFB3,6-phosphofructo-2-kinase/fructose-2,6-bisphosphate-3; PFKL, 
phosphofructokinase L; PGK 1, phosphoglycerate kinase 1; PAIII, plasminogen-activator 
inhibitor 1; PKM, pyruvate kinase M; TGF-a, transforming growth factor-cc; TGF-03, transforming 
growth factor-P3; TPI, triosephosphate isomerase; VEGF, vascular endothelial growth factor, 
UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, vimentin 
Se rn enza2003 
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1.6.2 Glycolysis 
Over seven decades ago classical biochemical studies showed that turnours 
have altered metabolic profiles and display high rates of glucose uptake and 
glycolysis (Dang and Semenza 1999). Normal cells utilize oxygen for efficient 
production of ATP by oxidative phosphorylation. Tumour cells rely on the less 
efficient glycolytic pathway to produce ATP, even in the presence of oxygen. 
Pyruvate at the end of glycolysis is converted to lactate via lactate 
clehydrogenase to replete NAD used in glycolysis (Fig 1.6). 
Glucose 
NAD ADP 
NAD NADH ATP 
4NIýj 
y 
Lactate P, -n vale 0 
, 
TCA cycle and oxidativa 
phosphcwylation 
MitochondriGn 
Fig 1.5 The production of lactate from pyruvate repletes NAD used in glycolysis. 
(Dang and Semenza 1999) 
Many glycolytic enzymes are raised in the serum of cancer patients (Cameron, 
1971). For example there is a close correlation of changes in glucose 
phosphate isomerase levels with progression of the disease. 
Phosphoglucornutase and ketose 1-phosphate aldolase is also often 
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raised in disseminated cancer. Increases of these enzymes also occur in 
cerebrospinal fluid in association with cerebral turnours but also in 
cerebrovascular accidents. The only glycolytic enzyme in routine use as a 
cancer marker in the serum however is lactate dehydrogenase (LDH). LDH is 
an independent factor for prognosis in all turnour types studied. LDH is raised in 
the serum independent of the nature of the tumour and the site of metastasis. 
There are 5 isozymes of LDH and only the hypoxia-inclucible one is raised in 
cancer (Yoshimura, Takemori et al. 1988; Koukourakis, Giatromanolaki et al. 
2003). This implies that tumour cells may be primarily up regulating hypoxia- 
inducible genes rather than glycolytic genes per se. One could hypothesize that 
a switch to glycolysis would be an advantage to cells in a hypoxic environment. 
The mechanism of such upregulation may be through HIF-1 given that the 
majority of enzymes in the glycolytic pathway are upreguated by HIF-1, 
although other oncogenic mechanisms also contribute (Fig 1.7). Tumours in 
contrast to normal tissues exist in an acidic environment of lactate and other 
acids. The intracellular pH of tumour cells, however, is maintained as it is in 
normal cells or even more alkaline which facilitates intracellular signaling. 
40 
pVHL L 11 
Glucose lirrernalý', 
KI 




C, Pl j 





Fiu: ý(.:,, se 1,6-b5phosphate 
TFI 






I u%- a 
L Ul H., . 1, 
Fig 1.6 HIF-1 upregulates the majority of enzymes in glycolysis. Oncogenes 
also upregulated glycolysis either directly or indirectly via HIF-1 (from (Dang 
and Semenza 1999)). C-myc may be responsible for the upregulation of HIF-1 
seen in normal healing skin wounds (see text), it is also turned on in the normal 
regeneration of liver tissue after resection (Robbins). 
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1.6.3 CA IX (carbonic anhydrase IX) 
CA IX is an extracellular enzyme attached to the cell membrane that catalyses 
the formation of bicarbonate and hydrogen ions from water and carbon dioxide 
thereby contributing to the acidic extracellular environment of tumours (Wykoff, 
Beasley et al. 2000). In cervical cancer CA IX is induced by hypoxia, and 
staining for CA IX correlates with tissue hypoxia measured by oxygen 
electrodes (Loncaster 2001). Substantial numbers of other studies indicate that 
it is a useful marker of hypoxia in tumour sections. (Airley, Loncaster et al. 
2003) (Koukourakis, Giatromanolaki et al. 2001; Olive, Aquino-Parsons et al. 
2001; Kaanders, Wijffels et al. 2002). Clinical studies correlated expression of 
CA IX with staining of bladder tumours by pimonidazole (Wykoff, Beasley et al. 
2000). The latter is a recognised marker of tumour hypoxia given to patients 
preoperatively and metabolised in hypoxic areas to an adduct that can be 
detected histochemically. 
1.6.4 Invasion and metastasis 
Proteins that are known to be upregulated by HIF-1 are known to play an 
established role in the pathophysiology of invasion. Urokinase plasminogen 
activator receptor (uPA), matrix metalloproteinase 2, cathepsin D, fibronectin 11 
vimentin and transforming growth factor alpha are all involved in digestion of the 
basement membrane and extracellular matrix. Degraded extracellular matrix is 
replaced by fibronectin and other proteins that are recognized by 
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integrins that are expressed on cancer cells. Unlike epithelial cells, malignant 
cells show mesenchymal characteristics in which intermediate filament 
production consists of keratins and vimentin, which promote the fluid structure 
required for motility, rather than simply keratin subtypes, which are characteristic 
of fixed epithelial cells. 
In an effort to characterize the metastatic genotype of bladder cancer Nicholson 
et al (Nicholson, Frierson et al. 2004) profiled gene expression changes in an in 
vivo bladder cancer lung-metastasis model in nude mice and compared results 
with gene expression profiles of 23 primary human bladder tumours, and found 
that the expression of four genes were consistently and progressively 
upregulated. Three of these genes, uPA, matrix metalloproteinase 14 (MMP14) 
and tissue inhibitor of meta I loprotei nase (TIMP2) have been shown to be 
hypoxia regulated (Graham, Forsclike et al. 1999; Ottino, Finley et al. 2004). In 
vitro invasiveness of MDA-231 breast cancer cells was increased by exposure 
to hypoxia and inhibition of uPA receptor inhibited this increase in invasion 
(Graham, Forsdike et al. 1999). Measurement of uPA protein and its receptor in 
plasma in 51 cancer cases prior to cystectomy and 44 men without cancer 
showed uPA to be independently associated with metastasis, disease 
progression and death from bladder cancer (Shariat, Monoski et al. 2003). 
Immunohistochemistry and in situ hybridization have shown higher expression 
of uPA to correspond with higher stage and grade in bladder cancer 
(Bhuvarahamurthy, Schroeder et al. 2004). 
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MMP14 is better known as membrane-type 1 matrix metalloproteinase (MT-1 
MMP) and is a major activator of pro-matrixmetalloproteinase-2 (pro-MMP2) on 
the cell surface and TIMP2 is known to inhibit this activation (Jo, Yeon et al. 
2000; Oblander, Zhou et aL 2005). MT-1 MMP has been shown to be a target of 
HIF-2 in renal cell carcinoma cells defective for VHL (Petrella, Lohi et al. 2005). 
MT-1 MMP deficient mice display a deficiency in growth and maintenance of the 
skeleton and soft tissues post-natally due to a loss of collagenolysis activity 
(Holmbeck, Bianco et al. 2004). Deleting or suppressing expression of MT1- 
MMP, in fibroblasts or tumor cells results in a loss of collagenolytic and invasive 
activity in vitro or in vivo and occurs independently of plasminogen, the 
gelatinase A/TIMP-2 axis, gelatinase B, collagenase-3, collagenase-2, or 
stromelysin-1 (Sabeh, Ota et al. 2004). 
Other in vitro and nude mouse experiments also suggest a role of hypoxia in 
invasion. Over-expression of HIF-1 by transfection in vitro colon carcinoma 
assays stimulates invasion in matrigel (Krishnamachary, Berg-Dixon et al. 
2003). Prior hypoxic exposure of melanoma cells before xenografting increases 
lymph node metastasis (Rofstad and Danielsen 1999; Rofstad, Rasmussen et 
al. 2002). Finally more hypoxic xenografts of a fibrosarcoma are significantly 




Angiogenesis is the growth of new blood vessels from the existing vasculature. 
One of the most potent angiogenic factors, often measured in picogram 
amounts, is vascular endothelial growth factor (VEGF). VEGF is induced by 
hypoxia in most cell types. Angiogenesis is a normal physiological process, vital 
in embryogenesis, wound healing and the female menstrual cycle. In addition to 
cancer, angiogenesis plays a role in the pathogenesis of diabetes, 
atherosclerosis, endometriosis and arthritis. Nearly a century ago it was 
observed that angiogenesis occurs around turnours (Goldman, 1907). Thirty 
years ago Judah Folkman proposed that' the population of tumour cells and the 
population of capillary endothelial cells within a neoplasm may constitute a 
highly integrated ecosystem' (Folkman 1971). Folkman went on to suggest that 
if tumours are absolutely dependent on angiogenesis, then angiogenesis is a 
very attractive therapeutic target. A considerable body of evidence now 
supports his hypothesis (Folkman 1990), some of the most important insights 
are listed below: 
1. The growth of tumours in an environment that does not permit vessel 
proliferation is limited to 1-2 MM3 . Rapid expansion occurs on 
transplantation to a permissive environment. 
2. Studies of hepatic metastases in rats show they are avascular prior to 
reaching 1 MM3 in size. Thereafter they are vascularised. 
3. Until vascularisation occurs at the base of human melanomas, 
metastases are rare. 
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4. Transfection of pro-angiogenic factors into tumour cells results in 
enhanced turnourgenicity. 
5. Inhibition of angiogenic stimulators results in reduced tumour growth in 
experimental situations. 
Microvessel counting in histopathological sections has also demonstrated 
angiogenesis to be an independent prognostic factor on multivariate analysis for 
breast cancer (Fox, Leek et al. 1995) and lung cancer (Macchiarini, Fontanini et 
al. 1992), prostate cancer (Jones and Fujiyama 1999) and muscle-invasive 
bladder cancer (Dickinson, Fox et al. 1994; Bochner, Cote et al. 1995; Jaeger, 
Weidner et al. 1995; Inoue, Slaton et al. 2000). 
Some positive results have been obtained for antiangiogenic approaches in 
clinical trials: In a randomised trial of an anti-VEGF antibody (bevacizumab) in 
metastatic renal cell cancer, the drug significantly prolonged time to progression 
of disease (Yang, Haworth et al. 2003). In a similar randomised trial in 
metastatic colorectal cancer there was a significantly longer median survival in 
the patients receiving the drug with standard chemotherapy compared to 
chemotherapy alone (Kabbinavar, Hurwitz et al. 2003). 
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1.8 Hypoxia, angiogenesis and bladder cancer 
0 
Fig 1.7 Superficial bladder cancer stained with CA IX (brown) and CD34 (red) 
(to show blood vessels). Note how the area of hypoxia starts at some distance 
from the vessels and goes right to the luminal surface. 
There are no direct measurements of tissue oxygen levels in human bladder 
cancer in vivo. Eppendorf electrode measures have not been performed 
probably due the to difficulty of accessing the tumour through a cystoscope. 
MRI measures of in vivo hypoxia are promising (Cooper, Carrington et al. 2000) 
but not yet performed in bladder cancer. However hypoxia markers demonstrate 
that bladder cancers are hypoxic at the luminal surface and around areas of 
necrosis. Clinical studies correlate expression of CA IX with staining of bladder 
turnours by pimoniclazole (Wykoff, Beasley et al. 2000). The latter is a 
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recognised marker of tumour hypoxia given to patients preoperatively and 
metabolised in hypoxic areas to an adduct that can be detected histochemically. 
In superficial bladder cancer CA IX is also coexpressed with VEGF (Wykoff, 
Beasley et al. 2000). The urine in the bladder is hypoxic and this luminal 
localisation of hypoxia induced genes in cancer has encouraged us to look for 
more such proteins that might be secreted into the urine. Since they are 
adjacent to the urine on the luminal surface they may be useful markers of 
recurrence as well as important mechanistically. 
Bladder cancers have been analysed in a similar way that Gray analysed 
histological sections of squamous lung carcinomata. Double staining for CA IX 
as a surrogate marker for hypoxia and CID 34 as a marker of blood vessels in 
12 bladder cancer cases showed that hypoxic areas were a mean distance of 
80ýtm away from 54 separate blood vessels stained (standard deviation = 
44ýtrn) (Turner, Crew et al. 2002). This distance of 80[tm fits well with the upper 
limit of the distance between normal capillaries. In the lungs the 
alveolocapillary barrier is only 1.5ýtrn for speedy gas exchange, whereas the 
intercapillary distance in ventricular muscle is 25ýtm, in brain 40ýtm and in 
resting skeletal muscle 80[im. 
HIF-1a and HIF-2a proteins were highly induced by hypoxia in four different 
bladder cancer cell lines (Jones, Fujiyama et al. 2001). All four cell lines 
(RT4, RT1 12,253J and EJ28) upregulate HIF-la protein in hypoxia on western 
blot. 
. Three of 
these cell lines also induce significant levels of HIF-2a with 
48 
hypoxia, and also during exponential growth in normoxia (EJ28). However 
immunohistochemistry and in situ hybridization (Onita, Ji et al. 2002) of 67 
cases showed that HIF-2a was not found in bladder cancer cells or normal 
tissues. Staining of serial sections with CD68 confirmed that stromal cells 
staining for HIF-2a were tumour associated macrophages and probably 
fibroblasts. No association with angiogenesis was found but they were 
significantly associated with perinecrotic areas. 
VEGF measured in the urine or in the tumour, and platel et-de rived endothelial 
cell growth factor (also known as thymidine phosphorylase) have been shown to 
be significant factors in mediating tumour angiogenesis in bladder cancer 
(O'Brien, Cranston et al. 1995). VEGF levels have been related to recurrence 
rates in superficial bladder cancer stage T1 or less (Crew, O'Brien et al. 1999). 
Thymidine phosphorylase activity is an independent prognostic factor in bladder 
cancer (Arima, Imazono et al. 2000), promotes VEGF expression (Brown, Jones 
et al. 2000), and promotes invasion (Jones, Fujiyama et al. 2002). Thymidine 
phosphorylase activity causes cellular oxidative stress which augments the 
levels of HIF1 produced by hypoxia (Brown, Streeter et al. 2005). 
Although angiogenesis correlates with grade of bladder cancer, assessment of 
angiogenesis did not help predict recurrence in 80 cases of superficial bladder 
cancer (Sagol, Yorukoglu et al. 2001). 
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1.8.2 Hypoxia, angiogenesis and invasive bladder cancer 
Angiogenesis is a prognostic factor independent of stage and grade in invasive 
bladder cancer and this correlation has been found in multiple studies 
(Dickinson, Fox et al. 1994; Bochner, Cote et al. 1995; Jaeger, Weidner et al. 
1995; Inoue, Slaton et al. 2000). The reason for this correlation is not clear but 
one hypothesis is that bladder tumours with high microvessel counts also have 
high levels of hypoxia and necrosis. There is good evidence from a study of 109 
breast tumours (Leek, Landers et al. 1999) and 56 gliomas (Chan, Leung et al. 
1998) that microvessel density correlates with necrosis. Turnours with high 
levels of angiogenesis are not necessarily well oxygenated. Blood vessels of 
tumours are not thought to be as functionally competent as their normal 
counterparts. They are known to be more permeable than normal blood 
vessels. Furthermore microvessel counting by the commonly used Chalkley 
method involves assessing angiogenesis at vessel hotspots, which may exist 
between areas of hypoxia and necrosis. Perinecrotic areas of tumours are 
known to be hypoxic and secrete VEGF boosting the VEGF secretion already 
occurring inside turnours due to growth factor stimulated synthesis of HIF-11a. 
Presence of hypoxia and necrosis may be the primary reason why some 
invasive bladder tumours have high levels of angiogenesis. 
The colocalisation of CA IX and VEGF near the luminal surface and in 
perinecrotic areas in bladder cancer suggests the mechanism for the 
upregulation of VEGF in bladder cancer is hypoxia. However the increased 
expression of eukaryotic translation initiation factor elF-4E was also 
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correlated with VEGF protein: mRNA ratios in superficial and invasive bladder 
cancers (Crew, Fuggle et al. 2000). elF-4E affects the rate of translation of a 
subset of mRNAs within the cell including HIF-1a (see figure earlier). elF-4E is 
downstream of growth factor signalling pathways. This suggests that VEGF may 
be upregulated in bladder cancer by growth factor stimulation of HIF-Ia protein 
synthesis and not merely by hypoxia. Many of the genetic changes, which are 
known to increase HIF synthesis, occur in bladder cancer. 50% of invasive 
bladder cancers have p53 mutation, 30% have lost PTEN, and up to 45% have 
H-ras mutation. 49% also stain strongly for EGF receptor (EGFR). (Neal, 
Sharples et al. 1990; Brandau and Bohle 2001). Autocrine growth stimulation 
involving HIF-1 may also occur in bladder cancer since HIF-1 transcriptionally 
activates TGF a which binds to EGFR. 
1.8.3 Hypoxia and the selection of malignant cells with an aggressive 
phenotype in invasive bladder cancer 
Lack of oxygen at the centre of turnours induces cell death and Vogelstein 
likened (Kinzler and Vogelstein 1996) the inside of solid turnours to a scene 
from Dante's Inferno with cells being born amidst the decaying remains of their 
ancestors. In such a hypoxic/necrotic environment cells that can resist death by 
hypoxia will be selected out. Hypoxia has been shown to induce p53 protein in 
non-mutant cells which may lead to apoptosis (Graeber, Peterson et al. 1994). 
In hypoxia therefore a p53 competent cell will be at a selective 
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disadvantage. Cycles of hypoxia and normoxia have been shown to select for 
p53 mutant cells in vitro (Graeber, Osmanian et al. 1996). p53 mutations are 
commonly found in invasive bladder cancer, are independently prognostic, 
(Esrig, Spruck et al. 1993) (Chatterjee, Datar et al. 2004) and show a significant 
association with angiogenesis (Bochner, Esrig et al. 1997). In superficial 
bladder cancer p53 mutations are rare, several studies have failed to find 
prognostic value for p53 independent of tumour stage and grade, and there is 
no correlation with angiogenesis (Reiher, Ozer et al. 2002). This suggests that 
p53 mutation and angiogenesis in invasive bladder cancer may be linked. A 
directly causal relationship seems unlikely when 27% of tumors that showed no 
evidence of p53 alterations exhibited high microvessel counts, and 26% of 
tumors with evidence of p53 alterations had low microvessel counts (Bochner, 
Esrig et al. 1997). A study in superficial bladder cancer also found a weak 
association between p53 status and microvessel counts (Reiher, Ozer et al. 
2002). Furthermore p53 status modulation in normal urothelial and bladder 
cancer cells does not affect VEGF or thrombospondin-1 (TSP-1) levels (Reiher, 
Ivanovich et al. 2001). Upregulation of VEGF and loss of TSP-1 are thought to 
be the prime regulators of angiogenesis in bladder cancer. The development of 
hypoxia and necrosis in invasive bladder cancer however could cause the 
selection of p53 mutants and angiogenesis. 
As previously mentioned one study of differentiated cells (murine embryonic 
fibroblasts and splenic B lymphocytes) has shown that loss of HIF-1a by 
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knockout abolished hypoxia-induced growth arrest and did this in a p53 
independent fashion (Goda, Ryan et al. 2003). Hypoxia caused an increase in 
the cyclin-dependent kinase inhibitor p2l, and it was also found that 
hypophosphorylation of retinoblastorna protein in hypoxia is HIF-lcc dependent. 
P53, p2l and retinoblastoma protein have all been shown to have prognostic 
value in invasive bladder cancer, an effect that is additive, (Chatterjee, Datar et 
al. 2004) such that if all three mutations were present 5 year survival was only 
8%, if no such mutations are present 5 year survival was 70%. Because all 
three of these proteins normally interact with HIF-1cc, it is highly likely that these 
mutations represent evolution within the tumour of mutations that can resist 
hypoxic growth arrest and/or death. It follows that the hypoxic and necrotic 
environment and downstream pathways of HIF-1cc in the bladder may be highly 
relevant to the evolution of an aggressive phenotype in bladder cancer. 
1.9 Gene expression profiling of hypoxia pathways 
DNA chips or microarrays are a sensitive and comprehensive way of 
investigating global gene expression at the RNA level but are not without pitfalls 
depending on their method of production and quality assessment (Knight 2001). 
The first application of a two-colour fluorescence hybridization scheme for 
expression profiling was carried out on a study of 45 genes of the flowering 
plant, Arabiclopsis thaliana (Schena, Shalon et al. 1995). Several groups 
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have used Genomic approaches to screen for genes upregulated by hypoxia 
and/or VHL deficiency. Early arrays screened less than 1000 genes in cell lines 
derived from foetal hepatic cells, hepatocellular carcinoma, and squamous cell 
carcinoma of the cervix and pharynx (Koong, Denko et al. 2000; Fink, Ebbesen 
et al. 2001; Scandurro, Weldon et al. 2001). Later arrays have screened 
progressively larger numbers of genes in cell lines from glioblastoma, 
pancreatic cancer and renal cell carcinoma (Lal, Peters et al. 2001) (Yoon, 
Buchler et al. 2001) (Wykoff, Pugh et al. 2000). Untransformed cells; 
keratinocytes, cervical cells and stromal fibroblasts (Denko, Fontana et al. 
2003) and renal proximal tubule cells (Jiang, Zhang et al. 2003), and their 
transformed counterparts have also been studied. 
The results of all these studies conclude: 
1. There is HIF-1 target genes, such as vascular endothelial growth factor 
(VEGF), glucose transporter 1 (GLUT1) and phosphoglyce rate kinase 1 (PGK1) 
that are induced by hypoxia in most cell types. 
2. There is significant heterogeneity in the transcriptional response to 
hypoxia between different cell types. Not only between different cancer types 
but also among cell lines that have been derived from cancers of the same 
histopathological type (e. g. 786-0 cells and RCC4 cell in renal cancer (Wykoff, 
Pugh et al. 2000), and among transformed and non-transformed cells of the 
same tissue type (Denko, Fontana et al. 2003) (Jiang, Zhang et al. 2003). In 
fact renal carcinoma cells seem to have evolved an alternative hypoxia 
signalling pathway compared with normal cells. 
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Hypoxia-induced pathways demonstrate different degrees of VHL- 
dependent and VHL-independent induction. For example for the renal cell line 
RCC4, the majority but not all genes induced by VHL loss investigated on 
northern blot were also regulated by oxygen (8 of 12 (Wykoff, Pugh et al. 
2000)). However in the renal cell line 786-0, using a genome approach, the vast 
majority (122 of 160) of genes induced by hypoxia in 786-0 VHL+ cells were not 
upregulated in the same cells by mutating VHL (Jiang, Zhang et al. 2003). 
However this may be because 786-0 cells do not express HIF-1a. 
For HIF-1 target genes therefore expression is induced by hypoxia in a cell- 
type-specific manner. HIF-1 alone cannot account for this cell-type-specific 
gene expression. Rather, it is the functional interaction of HIF-11 with other 
transcription factors that determines the subgroup of HIF-1 target genes that is 
inactivated in any particular hypoxic cell. Similar findings have been reported for 
p53-dependent gene expression (Yu, Zhang et al. 1999). 
1.10 Physiological and pathological hypoxia in the non-cancerous bladder 
Research into the tissue-specific hypoxia response of urotheliurn may also be of 
relevance to noncancerous bladder physiology and pathology. Normal 
physiologic bladder wall is probably not hypoxic as shown by negative CA IX 
staining in humans, blood flow measurements using fluorescent microspheres 
in rats and Doppler laser probes in pigs (Turner, Crew et al. 2002) 
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(Ghafar, Shabsigh et al. 2002) (Greenland and Brading 2001). However the 
normal bladder does experience periods of hypoxia on voiding. Studies of 
experimentally obstructed rat, dog and rabbit and pig bladders using implanted 
laser Doppler fibres show that on normal voiding blood flow to the bladder is 
temporarily reduced to an ischaernic level. In obstructed bladders this ischaernic 
period is significantly prolonged and this insult may be the cause of biochemical 
and neuronal alterations seen in such bladders. (Zhao, Wein et al. 1995; 
Greenland and Brading 2001; Ghafar, Shabsigh et al. 2002). One well 
controlled study which measured blood flow in rats and rabbits utilising a 
fluorescent microsphere technique and measured hypoxia by immunostaining 
for an injected Hypoxyprobe-1 (a chemical probe for hypoxia) showed that in 
the 1-2 weeks after obstruction the blood flow to the bladder wall and the 
bladder weight increases along with the appearance of hypoxia. This hypoxia is 
shown to affect first the mucosa, progressing through submucosa, lamina 
propria and into smooth muscle by 2 weeks of obstruction and continued for the 
four weeks duration of the experiment (Ghafar, Shabsigh et al. 2002). This 
supports the idea that hypoxia can drive angiogenesis and that such 
pathological angiogenesis may not be enough to correct the original hypoxia. In 
rabbits in such experiments a third phase of bladder decompensation is seen, 
where bladder weight reduces and scar tissue replaces the damaged muscle. 
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1.11 Bladder cancer trials of potential relevance to this thesis at the time of 
thesis submission (May 2008) 
UK Trials 
Name of trial Reference or Code of trial Note 
Phase 11 ARCON (Hoskin, Saunders et al. Completed trial, 
accelerated radiotherapy 1997; Hoskin, Rojas et al. morbidity and 
carbogen and 2005). treatment response 
nicotinamide. no worse with 
ARCON compared 
with historical controls 
of conventional 
radiotherapy. Phase 
III trials underway in 
the UK to formally 
assess cancer 
treatment efficacy. 
UK trial (Mount 
Vernon Hospital) 
Trial of radiotherapy vs (Harland, Kynaston et al. Completed trial 
intravesical BCG or 2007) conclusion - 
observation for T1 G3 radiotherapy is not 
bladder cancer +/- CIS. superior to more 
conservative 
treatment for T1 G3 
'high risk' superficial 
bladder cancer. 
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Standard or reduced BC2001 Starts 03/08/2001 
volume radiotherapy, Ends 30/04/2008 




A trial comparing surgery SPARE Starts 01/07/2007 
with treatment that may Ends 30/06/2014 
help people to keep their A pilot study and will 
bladder after invasive recruit 110 people. 
bladder cancer 
Antioxidant dietary SELENIB 
supplements 
Selenium and vitamin E 
Suramin intravesical for Phase I (Ord, Streeter et al. *See note at end 




Name of trial Reference or Code of trial Note 
Trial of Single-Dose SPI-611 EOquin@ is a 
Intravesical EOquin@) as NCT00461591 bioreductive prodrug 
a Surgical Adjuvant Phase III activated by 
Instilled in the Early reductase enzymes 
Postoperative Period in that are 
Patients Undergoing overexpressed by 
TUR-BT cancer cells to form 
the active alkylating 
agent. 
Monoclonal antibody inhibitors of VEGIF (USA) 
Cisplatin, Gemcitabine Phase 11 
and Bevacizumab in 
Combination for 
Metastatic Transitional HOG GU04-75 
Cell Cancer NCT00234494 
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Cisplatin, Bevacizumab, Phase 11 
and Gemcitabine 
Followed by Surgery, 
Bevacizumab, and MUSC-AVF-3312 
Paclitaxel in Treating MUSC-HR-1 5537, 
Patients With Locally GENENTECH-AVF-3312, 
Advanced Nonmetastatic NCT00268450, MUSC- 
Bladder Cancer That CTO-1 00892 
Can Be Removed By 
Surgery 
Trial of Gemcitabine, Phase 11 
Carboplatin, and 
Bevacizumab in 06-006 




Sorafenib and NCI-05-C-0022 
Bevacizumab in Treating 6750, NCI-6750, 
Patients With Refractory, NCT00098592 




Small molecule inhibitors of tyrosine kinase 
Sunitinib in Treating Phase 11 
Patients With MSKCC-06081 memorial 
Progressive Metastatic Sloane Kettering 
Transitional Cell Cancer NCT00397488 
of the Urothelium 
Sunitinib in Treating Phase 11 
Patients With Locally CASE-24806 
Advanced Bladder CASE 24806, PFIZER- 
Cancer GA6180CV 
VEGF Trap in Treating Phase 11 
Patients With Recurrent, CCC-PHII-76 
Locally Advanced, or 
Metastatic Cancer of the 
Urothelium 
Small molecule inhibitor of raf kinase and VEGF receptor (Sorafenib) 
Trial of Gemcitabine, Phase 11 
Carboplatin, and 






The use of VEGF inhibitors and tyrosine kinase inhibitors have had promising 
results and Professor RK Jain at Harvard medical school has postulated that 
VEGF inhibitors may work synergistically with chemotherapy not by rendering 
the tumour anoxic and so killing tumour cells as first suggested by Judah 
Folkman but by repairing tumour blood vessels made leaky by excess VEGF 
(which used to be called vascular permeability factor), reducing interstitial 
pressure and increasing the penetration of chemotherapeutic drugs and oxygen 
vital for radiotherapy. (Jain, Duda et al. 2006; Jain 2008) 
Since publication of this trial in 2005, there have been two papers one based on 
cell line work and one based on a mouse model of bladder cancer which 
strongly suggest that drugs to inhibit VEGF and or FGF will work synergistically 
with standard intravesical treatment mitomycin. The effect of adding such drugs 
to mitomycin halved the IC50 in vitro and increased absolute tumour shrinkage 
in the mouse model by 50% more. This is a very promising line of research. 
(Krause, Forster et al. 2005; Xin, Lyness et al. 2005) 
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1.12 Rational and objectives 
The hypothesis behind thesis was proposed by an article entitled 'Life (and 
death) in a malignant tumour. ' by Dr B Vogelstein MID of Johns Hopkins who 
has been credited with the discovery of the multistep pathway of carcinogenesis 
in colorectal cancer (Kinzler and Vogelstein 1996). 
In this article it was suggested that as a cancer grows it becomes hypoxic and 
the lack of oxygen at the centre of tumours induces cell death, and that it is the 
adverse internal environment of the tumour that results in the selection out of 
individual cells with a locally aggressive and metastatic phenotype. 
Hence the objectives of the thesis were: 
1. Investigate the transcripional response of an aggressive (grade three) 
bladder cancer cell line to severe hypoxia to find out how it is adapted to 
the hypoxic environment. And to validate the findings of this microarray in 
a panel of cell lines and untransformed cells for comparison. (Chapter 
Three) 
2. Investigate genes of potential in vivo relevance by cross-referencing the 
hypoxia-regulated transcriptome of the aggressive cell line (from 1) with 
an in vivo microarray of primary bladder cancer (39 cases data courtesy 
of E Streeter). (Chapter Four) 
3. Relate transcriptional changes of genes to histopathological evidence of 
necrosis and hypoxia and to levels of any secreted proteins in the urine 
of bladder cancer patients. (Chapter Four and Chapter Five) 
4. Investigate whether or not cancer cell lines are better at surviving severe 
hypoxia than a normal untransformed cell type (Chapter Five) 
5. Investigate whether or not a variety of markers of a hypoxic or 63 
necrotic tumour environment is or is not associated with an 
independently worse prognosis by multivariate analysis of a series of 
high grade and invasive bladder cancers. (Chapter Six) Also for 
superficial bladder cancer (Appendix VI). 
6. Investigate the transcriptional response of normal urothelium to hypoxia 
to see if it does differ in anyway from that in cancer cells. And also to see 
how other normal cell types (e. g. peripheral blood monocytes and T 
cells) differ in their response to hypoxia. 
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Chapter Two 
Materials and methods 
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2.1 Cell Culture 
2.1.1 Bladder cancer and HUVE cells 
Bladder cancer cells were maintained on polystyrene dishes in Dulbecco's 
Modified Eagles Medium (DMEM) and HEPES (EJ28,253J, 2T10) or RPMI 1% 
(RT112) supplemented with 1 mM glutamine (GibcoBRL, UK), 0.002mg/ml 
puromycin and 10% fetal bovine serum (FBS) (Globepharm, UK). Cells were 
maintained in a humidified atmosphere of 5%CO2 at 370C. Cells were plated at 
a minimum density of 5000cel IS/CM2 to achieve exponential growth. Cells were 
passaged by washing with phosphate buffered saline (PBS: 150 mM NaH2PO4 
and 150 mM NaCl), detached with trypsin (4 mg/ml trypsin in PBS). 
Human umbilical vein endothelial cells (HUVE cells) were grown on plates 
coated with 0.2% gelatine maintained in MCDB 131 (Invitrogen) containing 20% 
fetal calf serum (Sig ma-Ald rich), 100 units/ml penicillin, 100 pg/ml streptomycin, 
2 mM glutamine, 5 IU/ml heparin, and 50 pg/ml endothelial cell growth 
supplement (Sigma, Dorset, UK). HUVE cells were purchased from Clonetics 
BioWhittaker (Wokingham, Berkshire, UK) and were used up to the 8th 
passage. 
Hypoxia experiments were performed with the cells at 80-90% confluence. Cells 
were exposed to hypoxia by incubation in a humidified atmosphere of 
0.1%02, 
5%CO2and the remainder N2 in a NAPCO 7301 incubator (Precision Scientific, 
USA). 
2.1.2 Normal Urothelial Culture 
A strip of ice cooled fresh normal human ureter from a patient undergoing 
nephrectomy for renal cell cancer was placed in stripper medium (0.1 % EDTA, 
10mM HEPES, Trasylol 500,000 lU in 500ml Hanks Balanced Salt Solution 
minus calcium and magnesium) for maximum 6 hours at 4C. Over 6 hours and 
the cells tended to die or become infected. The urothelial lining was then 66 
scraped off, digested with collagenase for 30 mins and plated on collagen 
coated plates (Becton Dickinson, NJ) in Keratinocyte serum free medium with 
additives (25mg Bovine Pituitary Extract, 2.5ug Epidermal Growth Factor in 
500ml medium (Gibco, Invitrogen) and Cholera toxin 30ng/ml to prevent 
fibroblast growth). Penicillin 500OU/ml and Streptomycin 5mg/ml at 1: 100 and 
Gentamicin 5ug/ml were also necessary in the medium. Cells were passaged 
five times with EDTA 0.1% and trypsin versene before being exposed to 
hypoxia and RNA extracted as above. Morphology of the cultured urothelia 
fitted well with previous descriptions (Mackillop, Bizarri et al. 1985). In order to 
confirm the urothelial origin of the cultured cells cytospins were performed and 
cells stained for UR05 antibody, Cytokeratin 7; and Cytokeratin 20 confirming 
urotheliurn as the cell of origin (Chapter 4) (Cordon-Cardo, Bander et al. 1984; 
Dubeau and Jones 1987; Schaafsma, Ramaekers et al. 1989). 
2.1.3 Guards against cell line contamination, bladder cancer cell lines used and 
their provenance. 
Cross-conta mi nation of cell lines continues to be a widespread problem despite 
the fact that techniques have been available for researchers to check the 
identity of their cell lines. Cross-contami nation can occur in one of two ways: 
Clerical error (mislabelling frozen stocks or specimens) or poor culture 
technique when for some reason two cell lines get into the same culture. Cross 
contamination can be detected by karyotyping, isozyme analysis, HLA (human 
leucocyte antigen) typing, DNA fingerprinting (restriction fragment length 
polymorphism analysis), or more recently and conveniently DNA profiling of 
STIR (short tandem repeats). (Masters 2000; Masters 2002) 
The widespread problem of cross contamination of human cell lines was 
demonstrated in one large study of 252 cell lines studied by cytogenetics (N 
markers present and retained) and DNA fingerprinting. Cross-conta mi nation 
occurred in 18%. 45 cell lines were contaminated with other cell lines, mostly 
human (in 42 cases). Bladder cancer cell line T24 was among the worst with 4 
different identifiable cross contaminants none of which were even 67 
bladder cell lines (MacLeod, Dirks et al. 1999). 
EJ was the cell line used in this paper for the main hypoxic microarray analysis. 
This cell line was supplied by the CRUK (Cancer Research UK) facility where 
authenticity is verified by DNA profiling. However by the criteria of HLA-A-B-C 
typing and isozyme analysis EJ cells were shown in 1983 to be T24 cells 
(O'Toole, Povey et al. 1983). Both cells share HLA type Al, A3/Bl8/Cw5. 
Analysis of 15 different isozyme subtypes by starch gel electrophoresis in T24 
were identical to that in EJ a combination that would be expected in less than 
1% of the population. Bladder cancer cell lines RT4 and RT1 12 (also used in 
this thesis) were clearly distinct from T24 by HLA typing (O'Toole, Tiptaft et al. 
1982). 
T24 cells were established from a Swedish female patient CM aged 82 with 
long diagnosed bladder cancer. The tumour was grade III histologically when 
processed and cultured in February 1970 in Stockholm. Full characterisation 
was performed 18 months later with a generation time of 19 hours based on 31-1- 
thymidine labelling. Electron microscopy, cytology and karyotyping were also 
performed along with implantation into hamsters to confirm their malignant 
character (Bubenik, Baresova et al. 1973). In this same paper two other cell 
lines T15 and T22 were cultured for a short time but were not established in 
long-term culture. 
253J was established from a multiple TCC grade IV specimen in 1974 (Elliott, 
Cleveland et al. 1974). After the demonstration that many cell lines were 
contaminated with HeLa cells in 1974 by Walter Nelson-Rees, karyotyping in 
1977 proved that 253J had not been cross contaminated with HeLa cells (Elliott, 
Bronson et al. 1978). 
RT4 was established and described in 1970 (Rigby and Franks 1970). 
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2.1.4 Extraction and purification of Peripheral Blood Monocytes (PMBC) and T- 
cells (performed by Sarah Harten, Hammersmith Hospital, London) 
Blood (500mL) was taken from a willing volunteer (Dr Peter Hill) into tubes with 
heparin. lul heparin was used per ml of blood. Blood was then mixed 1: 1 with 
serum free medium (RPMI-sigma or AIMN lymphocyte medium from GIBCO 
Invitrogen) and carefully layered 1: 1 over a lymphoprep (Axis Shield , Oslo) 
gradient. Tubes were then centrifuged at 20OOrpm for 30 minutes with no brake. 
After centrifugation the PBMC interface layer was harvested, resuspended in 
medium and washed 2/3 times at 1800rpm. After washing the PBMCs were 
resuspended in a suitable volume of medium and placed in T75 plastic flasks 
(Helena) and incubated at 37 degrees temperature for 45 minutes. After this 
incubation the medium containing non-adherent cells was removed and the 
flask washed to remove any further non-adherent cells. The non-adherent cells 
were then spun down at 1800rpm and resuspended in a small volume (500ul). 
Selection antibodies were then added to the non adherent cells; anti CD8, 
CD19, CD33, Cd14, CD16 and CD56 (Diaclone and Caltag). The cells were 
incubated with the antibodies for 20 minutes at 4 degrees. After this incubation 
the cells were washed again (as above) and anti mouse-Ig Dynabeads were 
added (Dynal), amount depending on the number of cells at this stage 
(assuming four beads per CD4+ cell). Cells were incubated with beads for 45 
minutes with rotation, again at 4 degrees. Finally beads were removed from the 
solution using a bead magnet. The cells were washed once more and 
resuspended in a suitable volume. CID4 cells could then be counted and purity 
assessed by FACS. Purity was 90% or above. Activation of cells was done at 
this stage, by addition of CD3/CD28 beads, amount depending on the number 
of CD4+ cells. Cells were exposed to hypoxia by placing in a Concept 1000 
Ruskin hypoxia workstation set to 1% 02 immediately after activation, for 16 
h rs. 
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2.2.1 Extraction and Storage 
Both normoxic and hypoxic cell plates were washed in ice-cold PBS and placed 
on ice immediately on being removed from the incubator. RNA was extracted 
using 7ml Trireagent (Sigma, U. K. ) per 75 CM2 dish. Concentrations of RNA and 
purity were assessed on a mass spectrometer. RNA was stored initially in 75% 
alcohol at -800C (Sanger Array experiments) but then latterly for convenience in 
DEPC water at -800C. Tumours samples were collected with informed consent 
and approval from the Local Regional Ethics Committee. Samples were rapidly 
defrosted and homogenised in ice-cold Tri-Reagent (Sigma, UK). Phenol- 
chloroform based extraction of RNA and protein was performed according to the 
method of Chomczynski (Chomczynski 1993). 
2.2.2 Purity and Integrity 
RNA purity was assessed for the Sanger Arrays by ultraviolet spectrometry and 
integrity by running 1ýtg of total RNA on a 1% agarose / Tris-borate-EIDTA 
(TBE) gel prepared with 0.002% ethidium bromide. All samples were checked 
and any samples not showing two clear bands were excluded. Latterly for the 
Affymetrix arrays purity and integrity was assessed more thoroughly using the 
RNA 6000 Nano Assay in an Agilent 2100 bioanalyser (Agilent Technologies). 
Again any samples not showing two clear peaks of ribosomal RNA with 28S 
taller than 18S were not used. 
2.3 Sanger Microarrays 
2.3.1 Chips and Analysis 
Hver 1.2.1 cDNA microarrays were obtained from the Microarray Consortium, 
Sanger Centre, Hinxton, Cambridge. These contain 9,932 spotted samples of 
cDNA originating from the I. M. A. G. E. collections of the Human Genome 
mapping Project and Research Genetics, Hinxton, UK, and 468 chromosome 
22 gene-specific PCR products from the Sanger Centre, representing 
approximately 6000 human genes in total. The PCR products used are between 
0.2 and 1 kb in length. A Biorobotics MGII split pin arrayer ONA spots of 70 
between 1501Am and 250pm in size, with the cDNA binding covalently to the 
glass slide via a 5-prime aminolink incorporated into the first strand cDNA 
during PCR. Complementary second strand cDNA removed by subsequently 
boiling the slides and washing in ammonium solution, to leave single strand 
cDNA ready for hybridisation. The use of bacterial control cDNA distributed 
regularly throughout the slide allows sensitivity to be monitored over the whole 
surface. The limit of sensitivity estimated to be one cDNA molecule in 500,000. 
A GSI Lurnionics Scan Array 400 array-reader with Scanarray and Quantarraye 
software was used to analyse the slides. The analysed data was imported into 
GeneSpring@ software (Silicon Genetics, USA). Data was normalised internally 
by region on each chip (regional normalisation) to compensate for systematic 
variation over the surface of the array. The mathematical Lowess correction 
was applied to allow for non-linear fluorescence characteristics of the dyes. 
2.3.2 Generation of Fluorescently Labelled Single Stranded clDNA and 
Competitive Hybridization of Labelled Single-stranded clDNA 
Between 25-50IAg total RNA in 75% ethanol was mixed with 1 jil of the bacterial 
RNA cocktail and precipitated by the addition of 1/40th volume of 3M sodium 
acetate and storage at -70' C for 30 minutes. The RNA pellet was washed in 
70% ethanol and dried. The fluorescent dyes Cy3 and Cy5 come readily 
attached to the pyrimidine cytosine and this is mixed with the remaining 3 
nucleotides along with 30 pg of the total RNA sample and reverse transcriptase 
(Superscript 11 20OU/[d Gibco BRL). Selection of mRNA for reverse transcription 
is achieved by initially priming with anchored oligo-dT17 primers (17 thymine 
with a terminal adenine, guanine or cytosine) that hybridises with the poly-A tail 
found on mRNA. Reverse transcription is performed at 42'C using Superscript 11 
reverse transcriptase (Gibco), with. 60% of the added cytosine nucleotides 
labelled with Cy3 or Cy5 dyes (Amersham), thus fluorescence was incorporated 
into the reverse transcribed cDNA. At the end of this period the RNA hydrolysed 
by incubation at 70'C for 20 mins. Filtration to remove nucleotides and short 
oligomers performed using AutoSeq G-50 columns. The resulting single7l 
stranded cDNA was mixed with a second labelled cDNA from 30ýtg RNA 
sample 2 along with PolyA (2ýtg/ml) and cotl DNA (1ýtg/ml). This mix was 
precipitated in sodium acetate at -70C for 20 mins and the pellet formed 
resuspended in hybridisation buffer (5x SSC, 6x Denhardt's solution, 60mM Tris 
HCL pH7.6,0.12% sarkosyl, 48% formamide). This mix applied to the 
microarray slide. This slide placed in a hybridisation chamber humidified with 
hybridisation buffer. Incubation occurred at 470C for 12-24 hours. The slides 
then placed in a slide rack and washed in darkness in 3 different solutions 













Figure 2.1 Sanger cDNA 
microarrays. 
(I)M icroarray slides are 
constructed by a split-pin 
microarrayer, which 
applies spots of cloned 
cDNA 200 microns in 
diameter, 50 microns 
apart. A total of 9932 
elements for human genes, 
with 728 control points are 
used. cDNA is generated 
from samPle and control 






laser 17 laser 2 
transcription, incorporating 
Cy3 or Cy5 fluorescently 
labelled cytidine. cDNA 
from sample and reference 
RNA is competitively 
hybridised overnight onto 
the arrays. 
(11) The hybridised array is 
passed through a laser 
scanner, with the 
fluorescence spectrum due 
to the two dyes allowing 
distinction between paired 
computer 
analysis 
sample and reference 
cDNA. 
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2.3.3 Analysis of Genes Upregulated by Hypoxia (0.1 %) in Cell Line EJ28 
Using Sanger cDNA chips we analysed gene expression in an aggressive 
bladder cancer cell line EJ28 under normoxia and 16 and 24 hours hypoxia 
(0.1%). There were four replicates at each time point grown in separate plates 
compared with normoxic cells from the same passage harvested at the same 
time. 
2.3.4 Analysis of 38 Bladder Cancers Compared with Cancer Cell Line Panel 
(work and data courtesy Ed Streeter MID thesis) 
The labelled clDNA from 38 bladder cancers was hybridised to the chip with 
labelled clDNA from a panel of 11 cancer cell lines from different types of 
cancer. This provided a strictly controlled reference for each competitive 
hybridisation, a panel of 11 cell lines was harvested whilst in exponential growth 
in culture (SK23, NCI-H 1385, NCI-1-169, I M-9, MCF-7, OVCAR-3, MOLT- 
4, HEPG2, SW620, HT1376, W38). These cell lines were selected according to 
previously published work at Stanford (Perou, Sorlie et al. 2000), in order to 
reliably provide a constant level of expression over the vast majority of genes 
on the array. RNA was extracted according to the method of Chomczynski 
(Chomczynski 1993). The RNA was then resuspended in equal amounts in 
DEPC-treated water, and then aliquoted for storage at -800C. 
2.4 Real time Reverse Transcription Polymerase Chain Reaction (RTPCR) 
After reverse transcription of experimental RNA (SuperScript 11, Invitrogen) 
cDNA was diluted down to 0.5 ug/ul and final concentrations checked on 
spectrophotometer. The ABI Prism 7700 Sequence Detection System was used 
which is capable of analysing the fluorescence of more than one dye in a tube 
at a time. Sequencher software used to analyse the results and set baseline 
and threshold values. A commercial probe and primer set supplied by Applied 
Biosystems (U. S. A) was used for IGFBP-3, SLC16A3, RNAse4 MARCKS and 
Peroxiredoxin (PRDX5). The sequences of IGFBP3 and SCL16A3 were 
checked by BLAST search on Ensembi and NCBI databases (Table 2.1). 74 
Both probes hit the gene of interest, the SLC16A3 probe was seen to hit the 3' 






Table 2.1 Sequences used for Real Time Probes 
The probes of the genes of interest had FAM reporter dyes. Beta-2- 
microglobulin was chosen as a control gene as this is not known to be 
upregulated by hypoxia in the literature and was not upregulated by hypoxia in 
the cell line on the array. Subsequently RTPCR demonstrated no change under 
hypoxia. This gene was also sold as a control probe with primers limited which 
in theory prevents the relative abundance of this control gene affecting the 
assay of other genes of interest when used in the same tube. The relative 
technique of real time analysis was used looking at changes in cycle threshold 
between 3 normoxic replicates and 3 hypoxic replicates. Two to the power of 
the difference in average cycle threshold normoxia to hypoxia calculated the 
fold change. Each individual result was required to be within 0.5 cycles of each 
of the 3 replicates otherwise it was discarded. In addition if the cycle threshold 
of the 3 replicates of the control gene in normoxia differed significantly from 
hypoxia the result was also discarded. The most likely reason of this would be 
different starting amounts of cDNA in the normoxic and hypoxic master mix. 
This method is in contrast to other investigators that have used a varying control 
to normalise the probe to the amount of cDNA in each tube (Girault, Lerebours 
et al. 2002). PCR reactions were performed with the gene of interest and control 
probe in the same and separate tubes to be sure the probes were not 
interacting. 75 
2.5 Tissue Arrays 
2.5.1 Tumour Material and Array Construction 
Tissue arrays are accepted forms of rapidly assessing antibodies on a panel of 
turnours. The cores are significantly representative of the whole block so long as 
at least 2 cores are used and regional differences in staining are taken into 
account when selecting cores (Camp, Charette et al. 2000; Nocito, Bubendorf et 
al. 2001). 
98 consecutive cases of radical cystectomy for primary invasive transitional cell 
carcinoma of the bladder were retrieved with ethical approval and made into an 
array (coded TA 20 and TA 29). To gain an accurate assessment of necrosis in 
the three cystectomy stage pTO tumours, the previous transurethral resection 
specimens were reviewed and stained. A tissue array was also made from 
paraffin sections of the 39 superficial and invasive cases analysed on the gene 
microarray (coded TA 19). 
Whole sections of bladder cancer stained with haematoxylin and eosin (H&E) 
were reviewed under light microscopy. All representative tumour regions were 
encircled on stained slides by a consultant histopathologist (I. R. ) specialising in 
urological cancer and one researcher (J. 0). Carbonic anhydrase IX staining is 
known to be regional in bladder cancer and to occur more frequently around 
areas of necrosis (Wykoff, Beasley et al. 2000). We therefore selected two 1 mm 
cores from representative areas of tumour and if any necrotic areas existed 
another 2 perinecrotic cores. 
Cylinders with a diameter of 1.0mm were punched from the donor block and 
brought into a recipient paraffin block using a custom-made precision instrument 
(Beecher Instruments, Silver Springs, MID, USA). Up to 120 cores were placed 
in a single block in a standardized pattern with a core of tonsil tissue to mark the 
top left corner. Pairs of cores from the same tumour were placed in different 
array blocks. Sections of the resulting TMA blocks (5mm) were transferred to 
glass slides. 
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2.5.2 Staining and Scoring of Tissue Microarray (CAIX, HIFla, HIF2a, NIP3) 
For pre-staining slide preparation, all slides were heated at 60'C for 15 mins 
then dewaxed and rehydrated through citrate and graded alcohol (100% ethanol 
then 50% ethanol) and finally placed in 1xPBS for 5 mins. Endogenous 
peroxidase was blocked with hydrogen peroxidase from the EnVision kit (DAKO) 
for 5 mins. After any pre-treatment and primary antibody, secondary ChemMate 
(DAKO) polymer was added neat for 30 mins. Visualisation of staining was by 
DAB substrate. Slides were counterstained with haematoxylin before mounting 
in Aquamount (BDH, UK). CA IX 10% normal human serum was applied in PBS 
for 15 mins to block. The CA IX antibody M75 (Pastorekova, Parkkila et al. 
1997) (1: 50) was applied for 30 mins at room temperature. HIF la: Primary 
antibody ESEE122 (1; 30) applied for 60 mins. Pressure cook pre-treatment at 
1200C 15lbs/sq in, in Tris EDTA pH 9.0 for 3 mins. Trition X 100 0.2% in PBS for 
10 mins. HIF 2a: As HIFla except antibody used was EP190. NIPI 0.2% Triton 
X 100 0.2% in PBS 10 mins. 10% Normal Human Serum (NHS) in PBS. NHS 
tipped off slide. Rabbit polyclonal antibody to NIP3 described previously was 
(Ray, Chen et al. 2000) applied at 1: 400 in 10% NHS 30min. 
Scoring of whole H&E sections was done for necrosis at the time the cores were 
marked out (O=none, 1 =comedo or <5mm microscopic necrosis, 2=>5mm or 
gross necrosis). CA IX scoring was based on the intensity and area of 
membrane staining and a score of 0-3 was given, if the majority of the core 
showed intense membrane staining a score of 3 was given. Scoring of tissue 
arrays was done separately by two people, scores were compared and an 
agreement reached. The scores from two or more cores were both averaged 
and the maximum score was taken. Results were then analysed using both 
scores. 
2.5.3 Statistical Analysis 
Statistical analysis of associations between markers and tumour characteristics 
employed Chi squared test and Fisher's exact test. Survival curves used 
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the method of Kaplan and Meier. When comparing two survival curves the 
logrank test was used. Two tailed t-tests were used; p-values of less than 0.05 
were considered significant. If the logrank test showed a significant difference 
between groups then univariate and multivariate analysis was performed using 
nonlinear regression. This uses a statistical model to generate hazard ratios. 
Multivariate analysis was performed by a statistician (CH). 
2.6 Urine Collection 
Urine was collected with informed consent fresh from patients with histologically 
confirmed bladder cancer an average of 1 week before operation. Protease 
inhibitor cocktail (80ýtg 4-[2-aminoethyll-benzenesulphonylfluoride (AEBSF), 
200ýtg EDTA, 0.2ýtg leupeptin, 0.2ýtg pepstatin) was added and the sample spun 
at 30OOg for 10 minutes to remove debris. The supernatant was aliquoted and 
stored at -70'C until required. IGFBP-3 ELISA was performed using a 
commercial kit (Diagnostic Systems Laboratories). There were 71 superficial 
cancers, 18 invasive, 4 carcinoma-in situ, 30 patients who had previously had 
bladder cancer resected and were now clear, and 30 controls. Half of the 
controls were 43-80 years who had full investigations for haernaturia with no 
bladder cancer found, the other half were medical student volunteers age 18-30 
with no blood in the urine on dipstix. 
2.7 Affymetrix Arrays 
2.7.1 HG-U 133 Target 
The Human Genome U133 Set (HG-U133 A and HG-U133 B) is comprised of 
two microarrays containing over 1,000,000 unique oligonucleotide features (18 
mm in size, oligonucleotide length 25mers) covering more than 39,000 
transcript variants, which in turn represent greater than 33,000 of the best 
characterised genes. For each sequence represented in the array there are 11 
probe pairs. 78 
2.7.2 Oligonucleotide Probe Manufacture 
Affymetrix oligonucleotide probes are manufactured in situ on the chip through a 
combination of photolithography and combinatorial chemistry using 
technologies adapted from the semiconductor industry, Manufacturing begins 
with a 5-inch square quartz wafer. Because quartz is naturally hydroxylated, it 
provides an excellent substrate for the attachment of chemicals by covalent 
bonding. Each array holds over 500,000 probe locations, or features, within 
1.28 square centimetres. Each of these features harbours millions of identical 
DNA molecules. Probe synthesis occurs in parallel, resulting in the addition of 
an A, C, T, or G nucleotide to multiple growing chains simultaneously. 
2.7.3 Generation of biotin-labelled cRNA 
7-1 Oýtg total RNA at a minimum concentration of 1 mg/ml was used per sample. 
Reverse transcription was performed using Superscript 11 and a T7-dT24 primer 
to yield ss-cD N A. (T7-dT24 sequence 5'- 
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3'). 
Second strand synthesis was completed using Superscript ds-cDNA synthesis 
kit (Gibco), followed by a DNA phenol-chloroform-isoamyl alcohol purification 
step to exclude residual proteins. The dscDNA was then used to transcribe 
biotin-labelled cRNA via a five hour incubation at 370C with T7 RNA polymerase 
and biotin-labelled ribonucleotides (BioArray high yield RNA transcript labelling 
kit (Enzo)). RNA was purified using selective elution from a silica-gel based 
membrane (RNeasy mini kit (Qiagen)). This typically yielded 40-60ýtg cRNA. 
RNA fragmentation was performed at 94'C for 35 minutes in 1M Tris acetate 
pH8.1,500mM KOAc, 150mM MgOAc. Fragmented cRNA was mixed with 
eukaryotic hybridisation controls (Gene Chip eukaryotic hybridisation control kit 
(ENZO)) (Figure 2-2). 
2.7.4 Array Hybridisation 
This was kindly performed by Tracy Chaplin, at St Bartholomew's Hospital, 
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London. Samples were incubated on Affymetrix HU 1 33-A and B arrays for 16 
hours at 450C. Washing, and scanning were also performed by the microarray 
facility in London. 
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Figure 2.2 Affymetrix arrays labelled cRNA targets derived from the mRNA of 
an experimental sample are hybridized to nucleic acid probes attached to the 
solid support. By monitoring the amount of label associated with each DNA 
location, it is possible to infer the abundance of each mRNA species 
represented. 
2.7.5 Affymetrix Analysis 
The Array analysis generates a Detection p-value, which is evaluated against 
user-definable cut-offs to determine the Detection call. This call indicates 
whether a transcript is reliably detected (Present) or not detected 
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(Absent). Additionally, a signal value is calculated which assigns a relative 
measure of abundance to the transcript. Absolute intensities and calls (P or A) 
for each gene is imported into Genespring and analysed. 
Each gene is represented on the array by a series of different oligonucleotide 
probes. Each probe pair consists of a perfect match oligonucleotide and a 
mismatch oligonucleotide. The perfect match probe has a sequence exactly 
complementary to the particular gene and thus measures the expression of the 
gene. The mismatch probe differs from the perfect match probe by a single 
base substitution at the centre base position, disturbing the binding of the target 
gene transcript. This helps to determine the background and non-specific 
hybridization that contributes to the signal measured for the perfect match oligo. 
The Microarray Suite software subtracts the hybridization intensities of the 
mismatch probes from those of the perfect match probes to determine the 
absolute or specific intensity value for each probe set. 
The Detection algorithm also uses probe pair intensities to generate a Detection 
p-value and assign a Present (P), Marginal (M), or Absent(A) call. On average, 
as with Sanger Arrays sequences deemed significant or present have higher 
absolute intensities. Each probe pair in a probe set is considered as having a 
potential vote in determining whether the measured transcript is detected 
(Present) or not detected (Absent). The vote is described by a value called the 
Discrimination score [R]. The score is calculated for each probe pair and is 
compared to a predefined threshold Tau. Probe pairs with scores higher than 
Tau vote for the presence of the transcript. Probe pairs with scores lower than 
Tau vote for the absence of the transcript. The voting result is summarized as a 
p-value. The higher the discrimination scores are above Tau, the smaller the p- 
value and the more likely the transcript will be Present (defined as p<0.05). The 
lower the discrimination score below Tau, the larger the p-value and the more 
likely the transcript will be Absent (defined as p>0.065). The p-value associated 
with this test reflects the confidence of the Detection call. 
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Chapter Three 
Genearray analysis of an in vitro hypoxia transcriptome 
in a bladder cancer cell line and validation in a panel of 
cell lines and untransformed cells 
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3.1 Introduction 
In this chapter the results of experiments to define an in vitro hypoxia 
transcriptome are detailed and analysed. The anaplastic bladder cancer cell line 
EJ28 was chosen as a previous smaller array experiment looking in this cell line 
had identified genes that were upregulated by hypoxia and this had been 
confirmed by northern blot (Wykoff, Pugh et al. 2000). Genes that are known to 
be upregulated by hypoxia in other cell lines could also be expected to be 
upregulated. In a hypoxia time course experiment the anaplastic bladder cancer 
cell line EJ28 was exposed to 0.1% hypoxia for 16, and 24 hours, the mRNA 
extracted and competitively hybridised with mRNA taken from the same cells 
grown under normoxia to Sanger microarray chips. There were two biological 
replicates and two dye reversed replicates at each time point as well as a self- 
self control. 
3.2 Results 
3.2.1 Genearray results 
Bladder cancer cell line EJ28 which is derived from an invasive tumour was 
examined in vitro hypoxia at 0.1% oxygen. In order to minimize false positive 
results and generate a reliable shortlist, only those genes with raw absolute 
values of >1000, upregulated >2-fold in at least 6 of 8 replicates (four at 16 
hours and four at 24 hours) were selected. This would ensure a reliable result 
but perhaps at the cost of a lower sensitivity. From scatter plots of the self-self 
control it is clear that at lower intensities the fold-regulation has more random 
error. Therefore a relatively high cut-off point for intensity of 1000 units was 
chosen. 
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Figure 3.1 Self/self control test of the Sanger array log scale. cDNA from 
identical EJ28 bladder cancer cell line samples one labeled with Cy5 (green) the 
other with Cy3 (red) were competitively hybridized. At lower intensities (<1000) 
there is visible variation around the true value of 1 represented by the blue 
diagonal Ii 
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Of 6000 genes analyzed only a small subset of 32 (0.53%) were repeatably 
observed to be upregulated on the gene array (Table 3.1). Of these 32 genes 
were two of the three previously known to be upregulated by hypoxia in this cell 
line on Northern blot (Cyclin G2 and DECII) as well as genes known to be 
upregulated by hypoxia in other cell lines (e. g. VEGF). Adrenomedullin (ADM) 
was upregulated 17-fold and Insulin-like growth factor binding protein 3 (IGFBP- 
3) was upregulated 12-fold. They were the most upregulated mRNAs with 
VEGF less at 2.5 fold upregulation. Nearly all genes either increased or retained 
the upregulation found at 16 hours at 24 hours. These genes divided up into 
functional groups typical of hypoxia induced genes (Harris 2002) (Table 3-1). 
Several genes not previously known to be upregulated by hypoxia included 
Ribonuclease 4 RNAse4 3.1 -fold, monocarboxylate transporter family member 4 
(SLC16A3 also called MCT4), Preferentially expressed antigen of melanoma 
PRAME 4.9-fold, and Importin Beta 3 4.1-fold. Not listed because it was not 
validated later was the protein kinase C substrate MARCKS which appeared 
upregulated 2.2 fold at 16 hours. The ESTs do not relate to any known genes 
(last checked August 2005). 
Table 3.1 (next 2 pages) Mean fold changes of all 32 genes upregulated more 
than 2-fold by hypoxia (0.1%) at 16 and 24 hours in cell line EJ28. Microarray 
result of 8 biological replicates; genes had to be upregulated more than 2-fold 
with in cell line EJ28. Microarray result of 8 biological replicates; genes had to 
be upregulated more than 2-fold with high raw signal intensity (>1000 units) in 
more than 6 of 8 replicates to avoid false positives and be included in this list 








Known to be hypoxia-upregulated in other cell lines 
1 3.4 17 Adrenomedullin (ADM) Vascular Tone 
Insulin-like growth factor binding protein 3 Apoptosis 2 2.6 12.1 (IGFBP-3) 
3 2.9 8.2 n-myc downstream regulated protein 1 (NDRG1) Cell Cycle 
4 5.3 6.6 BCL2 binding protein NIP3 (NIP3) Apoptosis 
Inducible 6-phosphofructo-2-kinase (PFKFB3) Glucose 
2.7 4.7 
2.4 4.7 
7 2.2 4.4 
3.1 4.2 
9 2.3 3.9 
10 2.2 3.8 
11 2.5 3.7 
12 3.2 3.2 
13 2.9 3.1 
14 1.9 3 
15 1.8 2.6 
16 2.5 2.5 
17 2.1 2.5 
18 1.9 2.5 
19 2.4 2.5 
Lysyl Hydroxylase (PLOD2) 
MAX interacting protein 1 (MAX 1) 
Glucose Transporter 1 (GLUT 1) 
1,4-Alpha Glucan Branching Enzyme (HGBE) 
Cyclin G2 (CCNG2) 
Proline-4-hydroxylase (P4HAl) 
Adenylate Kinase 4 
Aldolase C (ALDO C) 
Prolyl-4-hydroxylase alpha subunit 
Haern oxygenase 1 (HMOX1) 
EGL9 Homologue 1 
Testis-specific lactate dehydrogenase (LDH C) 
VEGF 
Adenylate Kinase 3 (AK3) 
Dual Specificity Phosphatase 1 
20 1.7 2.4 (DUSP1/CL100/MKP1) 
21 1.7 2.1 DEC 1 
Glucose-6-Phosphate isomerase (GPI) 
22 2.6 2.1 
23 2.1 2.1 
Fructose-B isphosp hate Aldolase A 































No. Fold-change GENE FUNCTIONAL 
at hypoxia GROUP 
16 24 
Hours Hours 
Not previously known to be hypoxia regulable 
-24 2.8 8.2 Solute carrier family 16 member 3 (SLC16A3) 
Preferentailly expressed antigen of melanoma 
25 4.5 4.9 (PRAME) 
Importin Beta 3 
26 2.8 4.1 
RNAse 4 
27 1.9 3.1 











29 3 3.9 50378 
_A 
EST 
30 3.2 3.3 50022 
_A 
EST 
31 3.5 3.3 31564 
_B 
EST 
32 2.1 2.4 21875 
_A 
EST 
Table 3.1 Mean fold changes of all 32 genes upregulated more than 2-fold by 
hypoxia (0.1%) at 16 and 24 hours in cell line EJ28. Microarray result of 8 
biological replicates; genes had to be upregulated more than 2-fold with in cell 
line EJ28. Microarray result of 8 biological replicates; genes had to be 
upregulated more than 2-fold with high raw signal intensity (>1000 units) in 
more than 6 of 8 replicates to avoid false positives and be included in this list 
(ECMM=Extracellular Matrix/Collagen Metabolism). 
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3.2.2 Validation of microarray results 
In order to validate the results of array analysis the technique of Reverse 
Transcription Polymerase Chain Reaction (RTPCR) was initially used (Figure 
3.2a and b). Products of PCR amplification of cIDNA prepared from RNA 
extracted from cell lines was compared on an agarose gel after a fixed number 
of PCR cycles. However many of the gene fold changes were in the range 2-8 
fold and RTPCR was found to be too insensitive to reliably detect these 
changes. 
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Figure 3.2a An example of a RT-PCR result. n=normoxia replicate in sets of 3, 
h=hypoxia replicate in sets of 3. lGFBP3 with beta actin control (reaction 
stopped at 32 cycles) confirms upregulation of lGFBP3 in bladder cancer cell 
lines EJ28 RT4 RT112 and 2T10 253J(equivocal), normal urothelium and 
HUVE cells. 2% agarose gell with ethidium bromide. 
90 
Figure 3.2b An example of a RT-PCR result. n=normoxia replicate in sets of 3, 
h=hypoxia replicate in sets of 3. IGFBP3 with beta actin control (reaction 
stopped at 32 cycles) also confirms upregulation of lGFBP3 in bladder cancer 
cell lines EJ28 RT4 RT1 12 and 2T1 0. Remaining three genes at 38 cycles: CA 
IX, HRC1 (HRAS associated gene (Weitzel, Kasperczyk et al. 1992)) and 
PRAME confirmed as upregulated by hypoxia in EJ28.2% agarose gell with 
ethidium bromide. 
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Furthermore actin was used as a control in these experiments and there has 
been a report that actin is induced by hypoxia (Zhong and Simons 1999). 
Comercially available genes to act as controls for Real-time RTPCR were 
literature searched to ensure there were no reports of hypoxia regulation, data 
from the hypoxia array also suggested that the genes Beta-2-Microglobulin 
(Figure 3.3) and Peroxiredoxin would be suitable; neither was upregulated by 
hypoxia on the in vitro array. 
Figure 3.3 Hypoxia array result for fold change in Beta-2 microglobulin under 
hypoxia. Four replicates at 8,16 and 24 hours all showed no significant change. 
Apart from the two control genes four genes in total were selected for validation 
and further investigation in other cell lines; IGFBP-3, RNAse4, SLC16A3, 
MARCKS. lGFBP3 was selected because it was the most upregulated gene on 
the in vitro and in vivo arrays (see Chapter 4). RNAse4, SLC16A3 and 
MARCKS were selected because they have not been previously reported to be 
upregulated by hypoxia in cell lines and were significantly upregulated in 92 
some bladder cancers on the in vivo array. RNAse 4 comes from the same 
family as the archetypal angiogenic factor Angiogenin which is known to be 
upregulated in the blood of bladder cancer patients, and SLC16A3 is a lactate 
transporter. MARCKS was upregulated by hypoxia in EJ28 only 2.1 fold but 
appeared strongly upregulated on the in vivo array giving reason for further 
investigation. 
Once real-time RTPCR had confirmed the upregulation by hypoxia in EJ28 
other bladder cell lines, cultured normal urothelium, breast cell lines, human 
umbilical vein cells and fresh monocytes were also investigated. The culturing 
of human normal urothelial cells was performed by the current investigator and 
required several attempts. Initial cultures were killed by fungal or bacterial 
infections. Normal urothelia was grown to 6 passages. The origin of the cells as 
normal urothelia was confirmed by immunohistochemical staining of cytospun 
lifted cells with cytokeratin 7,20 and antibody Uro 5 (Cordon-Cardo, Bander et 
al. 1984; Dubeau and Jones 1987; Schaafsma, Ramaekers et al. 1989) (Figure 
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Figure 3.4 A Cultured normal urothelia grown from fresh normal ureter from a 
nephrectomy specimen. B, C, D Cytospin samples of the cultured cells was 
positive for Uro 5 (B) Cytokeratin 7 (C) and Cytokeratin 20 (D) confirming 
urotheliurn as the cell of origin (see text for references). 
94 
12 14 16 18 20 22 24 26 28 30 22 24 26 28 30 32 34 36 38 41 
REAL TIME PCR CYCLES 
Figure 3.5 An example of a real time RT-PCR result. Graphs were produced but 
results were analysed based on raw numerical data. Normal urothelium grown in 
culture. Right graph; total of six lGFBP-3 probe replicates normoxia vs. hypoxia 
show a significant (p=0.0003) average difference of 2.1 cycles at the threshold 
(equating to 4.6 fold upregulation). Left graph; six beta-2-microglobulin 
replicates performed with the identical experimental samples, reagents and 
processing in separate experimental tubes (three normoxia and three hypoxia) 
show no significant change. 
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IGFBP3, RNAse4 and SLC16A3 were confirmed to be upregulated by 
hypoxia in all bladder cancer cell lines examined and other cell lines (Table 
3.3). Of the untransformed cells SLC16A3 RNA was markedly upregulated 
by hypoxia in HUVE cells but not in cultured normal urotheliurn nor in fresh 
monocytes. RNAse 4 like IGFBP-3 was upregulated by hypoxia in the cell 
lines and normal urothelial cells. A typical result for RTPCR is shown 
(Figure 3.4). The control gene Beta-2-microglobulin showed no significant 
change by comparison. Nor did a second control gene Peroxiredoxin 
selected from the hypoxia array by its lack of fold-change (Table 3.2). 
MARCKS was upregulated by hypoxia 2.1-fold on the in vitro array and also 
more than 2-fold in more than 20 tumours on the in vivo array. However 
MARCKS upregulation in the cell line panel was not confirmed (Table 3.2) 
3.3 Discussion 
Genes up regulated in EJ28 could be classified into groups typical of 
hypoxia inducible genes (Table 3.4). EJ28 readily upregulated genes 
involved in glycolysis and nucleotide metabolism as expected as hypoxia 
increases demands on glycolysis and its energy transfer molecules AMP 
and ADP. Cell cycle and putative apoptotic genes (CCNG2 lGFBP3 NIP3 
ABLII) were also upregulated but it is not clear whether some of these 
genes (e. g. IGFBP3) promote apoptosis or proliferation in vivo (vide infra). 
EJ28 also markedly upregulated genes involved in acid base regulation, 
angiogenesis and vascular tone. 
3.3.1 ND RG 1 
N-myc downstream-regulated protein 1 (NDRG1) was upregulated 8-fold. 
NDRG1 is known to be upregulated by hypoxia (Lachat, Shaw et al. 2002) 
and in many human cancers (Cangul 2004). C-myc is an oncogene whose 
normal physiological function is the normal proliferative maintenance of and 
wound healing in skin, as has been recently demonstrated in skin 
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epithelium-specific c-myc knock-out mice (Zanet, Pibre et al. 2005). C-myc 
upregulation has also been demonstrated to be physiologically upregulated 
in healing skin wounds in rats (Fu, Gu et al. 2003). C-myc and n-myc are 
members of the same family and similar enough for n-myc to replace c-myc 
in mice with no adverse effects on development or adulthood (Malynn, de 
Alboran et al. 2000). C-myc amplifications are known to occur in 
approximately 40% of bladder cancers and are strongly associated with 
markers of biological aggressiveness such as stage and grade and 
proliferation index (Sauter, Carroll et al. 1995). It is tempting to speculate 
that NDRG1 has a role in the biological aggressiveness of bladder cancer 
too. 
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Functional group Gene Fold 
change 
Vascular Tone Adrenomedullin (ADM) 17 
Haern oxygenase 1 (HMOX1) 2.6 
Apoptosis Insulin-like growth factor binding protein 3 12.1 
(IGFBP-3) 
BcI-2 binding protein NIP3 6.6 
Cell Cycle N-myc downstream regulated protein 1 8.2 
(NDRG1) 
Cyclin G2 (CCNG2) 3.8 
Protooncogene ABL1 2.9 
Acid Base Solute carrier family 16 member 3 (SLC1 6A3) 8.2 
Testis-specific lactate dehydrogenase (LDH-C) 2.5 
Glucose Metabolism Inducible 6-phosphofructo-2-kinase (PFKFB3) 4.7 
Glucose Transporter 1 (GLUT 1) 4.2 
1,4-Alpha Glucan Branching Enzyme 3.9 
Aldolase C 3.1 
Glucose-6-Phosphate isomerase 2.1 
Fructose-Bisphosphate Aldolase A 2.1 
Oxygen sensing/ECMM Lysyl Hydroxylase (PLOD2) 4.7 
Proline-4-hydroxylase (P4HA1) 3.7 
Prolyl-4-hydroxylase alpha subunit 3 
EGL9 Homologue 1 2.5 
Nucleotide metabolism Adenylate Kinase 4 3.2 
Adenylate Kinase 3 2.5 
Antigen Preferentailly expressed antigen of melanoma 4.9 
(PRAME) 
Transcription factor MAX interacting protein 1 4.4 
Nuclear pore protein Importin Beta 3 4.1 
Antimicrobial / RNAse 4 3.1 
Angiogenesis? 
Angiogenesis VEGF 2.5 
Cell signalling Dual Specificity Phosphatase 1 2.4 
(DUSP1/CL100/MKP1) 
Differentaition Dec-0 1 2.1 
Table 3.4 Functional groupings of the 32 hypoxia inducible genes in 
bladder cancer cell line EJ 28. 
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3.3.2 IGFBP-3 
IGFBP-3 mRNA is known to be hypoxia-inducible in a number of cell lines 
and these results show that this is also true of bladder cell lines with 
upregulation 5 to 38 fold. Nor is this upregulation specific to cancer, with 
upregulation in human cultured urothelium (4.6 fold) and HUVE cells (7- 
fold). 
Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is known to 
block IGF action and inhibit cell growth (Baxter 2001; Firth and Baxter 
2002). IGFBP-3 is thought to act by sequestering free IGFs or, possibly, 
acts via a novel IGF-independent mechanism. Supporting its role as a 
primary growth inhibitor, IGFBP-3 production has been shown to be 
increased by cell growth-inhibitory agents, such as transforming growth 
factor-beta (TGF-beta), and the tumor suppressor gene p53 (Rajah, 
Valentinis et al. 1997). IGFBP-3 has also been shown to have an apoptotic 
function independent of IGFs and IGF receptor and p53 in the p53 negative 
prostate cancer cell line PC-3. In the same cell line TGFbetal, a known 
apoptosis-inducing factor was shown to induce apoptosis by the induction 
of IGFBP3 (Rajah, Valentinis et al. 1997). 
However other in vitro studies suggest IGFBP3 is involved with stimulation 
of proliferation and DNA synthesis. IGF-1 on its own has no nuclear 
localisation signal but IGFBP-3 does. Endogenously expressed IGFBP3 in 
transfected bovine mammary cell culture makes them more sensitive to 
IGF-1 stimulation of DNA synthesis than vector only transfected controls 
(Grill and Cohick 2000). In experimental wounds caused by scratching a 
confluent layer of opossum kidney cells, the IGFBP-3/IGF-1 complex 
locates to the nucleus in proliferating cells near the wound edge but not in 
resting cells at a distance from the wound (Li, Fawcett et al. 1997). IGFBP-3 
has been shown to have a stimulatory effect on the growth of sheep smooth 
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muscle bladder cells (Weinzimer, Gibson et al. 2001); an intriguing finding 
given the link between bladder outflow obstruction, hypoxia and bladder 
muscle hypertrophy (see introduction). Topical administration of IGFBP-3 
and IGF-1 together reverse the defect caused by corticosteroids in healing 
skin wounds of rats better than IGF-1 alone (Hamon, Hunt et al. 1993). 
Thus IGFBP-3 may potentiate or sensitise cells to the proliferative effects of 
IGF-1. 
Nuclear translocation and phosphorylation of IGFBP-3 is described 
(Schedlich, Nilsen et al. 2003) (Schedlich, Young et al. 1998), with 
phosphorylation increasing nuclear import of IGFBP-3, and decreasing its 
affinity for IGF with release of IGF. The import mechanism involves 
interaction with Importin Beta (Schedlich, Le Page et al. 2000). Interestingly 
this gene was also in our list of 32 genes upregulated (4.1 fold) by hypoxia 
on the array and is not previously reported to be upregulated by hypoxia. 
Thus IGFBP-3/Importin Beta may be an important pathway upregulated by 
hypoxia in bladder urothelium. 
Animal studies suggest that the initial physiological response of urothelium 
after 24 hours of hypoxic stress is proliferation of the basal cell layer with a 
concomitant decrease in TGF beta levels. TGF beta is known to be 
associated with differentiation of prostate cancer cell lines and its down 
regulation in proliferating bladder urothelium suggests a similar role in 
bladder. IGFBP-3 anti proliferative signaling appears to require an active 
transforming growth factor beta (TGF-beta) signaling pathway, and IGFBP- 
3 stimulates phosphorylation of the TGF-beta signaling intermediates 
Smad2 and Smad3. (Baxter 2001) 
IGFBP-3 may play a significant role in endothelium. In a mouse xenograft 
model lGFBP-3 RNA was overexpressed in tumour endothelial cells 
(Schmid, Bisoffi et al. 2003). Addition of lGFBP-3 in vitro reverses VEGF- 
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induced proliferation of HUVE cells in an IGF-independent fashion (Franklin, 
Ferry et al. 2003). Thus IGFBP-3 may act as a direct apoptotic response to 
hypoxia, balancing the proliferation of endothelium caused by VEGF in 
hypoxic areas. If so, this implies that there are major selective mechanisms 
in vivo to overcome this pathway and suggests that antagonising the IGF1 
receptor could have high selectivity in cancer, with endogenous IGFBP-3 
synergising with such inhibition. 
As lGFBP3 is a secreted protein its levels were also measured in the urine 
of bladder cancer patients (Chapter 5). 
3.3.3 RNAse4 
The upregulation of RNAse4 by hypoxia was confirmed. Upregulation by 
hypoxia does not appear to be cancer-specific as we also found RNA levels 
induced in normal urothelium. The human enzyme is secreted into plasma 
(Terzyan, Peracaula et al. 1999). But very little about its function is known. 
The gene (Rosenberg and Dyer 1995) shares various identical 5'- 
untranslated regions on its mRNA with angiogenin, suggesting that 
expression of these proteins is under similar control, with obvious 
implications for their biological activities (Strydorn 1998). Angiogenin is 
known to stimulate angiogenesis (Folkman and Klagsbrun 1987) but has 
recently been found to play an antimicrobial role as part of the innate 
immune system as well (Hooper, Stappenbeck et al. 2003). Angiogenin 
protein is upregulated by hypoxia in cervical and melanoma cell lines 
(Hartmann, Kunz et al. 1999; Pilch, Schlenger et al. 2001) and is raised in 
the blood and tumours of patients with bladder cancer (Miyake, Hara et al. 
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1999). Since the surface of bladder cancers is hypoxic the levels of 
angiogenin in urine were also looked at (see Chapter 5). 
3.3.4 SLC16A3 
The lactate transporter SLC16A3 is also confirmed to be a hypoxia- 
regulated gene. This occurred in all six cell lines examined. Of the 
untransformed cells SLC16A3 was markedly upregulated in human 
umbilical vein cells 68-fold but not in cultured normal urothelium nor fresh 
monocytes. This suggests a possible physiological role for SLC16A3 in 
endothelial cells under hypoxia. It is a member of the proton-linked 
transmembrane monocarboxylate transporter (MCT) family with high 
affinity for lactate. It is also known as MCT4 (previously known as 
MCT3)(Halestrap and Price 1999). Transfection of a monkey kidney 
epithelial cell line (COS) and Xenopus oocytes with MCT4 stimulates lactate 
transport. (Kirk, Wilson et al. 2000; Manning Fox, Meredith et al. 2000). 
MCT 4 is in most tissues but is particularly high in the white skeletal muscle, 
white blood cells and cell lines suggesting it may be of particular importance 
in tissues that rely on high levels of glycolysis for ATP production and hence 
lactate production (Wilson, Jackson et al. 1998; Halestrap and Price 1999) 
(Juel and Halestrap 1999). 
3.3.5 HRC1 
In an earlier analysis of the array data HRC1 was one gene that was 
upregulated on the in vitro array but in less than 7 of 8 replicates. It was 
however confirmed as upregulated by hypoxia on standard reverse 
105 
transcription-PCR (see Figure 3.1). Molecular genetic alterations of 
chromosome 11p15.5 are a common finding in human cancer and this 
region contains HRC1, the protooncogene HRAS1 and the ribonuclease- 
angiogenin inhibitor RNH (Weitzel and Patel 1994). Furthermore HRAS1 
and HRC1 are known to be upregulated in the EJ28 bladder carcinoma cell 




The comparison of in vitro data with in vivo array 
data and in vivo staining 
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4.1 Introduction 
This thesis benefited much from in vivo array data courtesy of Mr E 
Streeter. The in vivo array data came from samples of 39 transitional cell 
carcinomas of the bladder competitively hybridised to a Sanger microarray 
chip with reference RNA pooled from 11 cell lines from a panel of various 
cancers (see method for details). As the same type of Sanger chips were 
used for the in vivo array there was data available for all genes identified as 
hypoxia-inducible on the in vitro array. Both superficial (Ta, T1) and invasive 
(T2, T3) tumours were used on this array as listed in Table 4.1. Of 6000 
genes on the in vivo array, 70 (1.2%) were upregulated more than 2-fold in 
over 30 tumours. The results for hypoxia-regulated genes identified in EJ28 
are analysed in this chapter. 
4.2 Results 
4.2.1 Hypoxia inducible genes upregulated on the in vivo array 
Upregulation on the in vivo array data was defined as upregulation more 
than 2-fold, in more than 5 of the 39 tumours. As with the in vitro array, data 
with raw signal intensity <1000 was excluded to reduce erroneous fold- 
changes caused by the increased random error seen at lower intensities. Of 
the 32 genes upregulated by hypoxia in vitro, 8 genes were upregulated 
more than 2-fold in more than 5 of the 39 tumours (red in Figure 4.1). 
VEGF, which is known to be expressed in bladder cancer was upregulated 
2.5-fold by hypoxia and 2 to 18-fold in 31/39 tumours making it the second 
most frequently upregulated hypoxia-inducible gene on the in vivo array. 
The most highly and frequently upregulated gene in both arrays however 
was the mRNA IGFBP-3. This was upregulated up to 12-fold 
by hypoxia in 
vitro and from 2 to 100-fold in 33/39 tumours compared to the cell 
line 
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panel. The other 6 genes with more than 2-fold upregulation in more than 5 
tumours arrayed were CCNG2 in 30 tumours, NDRG1 in 18 tumours, 
PFKFB3 in 17 turnours, RNAse4 in 10 tumours, Adrenomedullin (ADM) in 8 
turnours and Glucose transporter 1 (GLUT-1) in 6 tumours. The cumulative 
fold changes for all 8 genes are plotted for each tumour (Figure 4.2). It can 
be seen that fold changes for IGFBP-3 were greater than for other genes. 
Of the genes not previously reported to be upregulated by hypoxia were 
RNAse4 and SLC16A3. RNAse4 was significantly upregulated on the in 
vivo array in 10 tumours. Although signal was low for SLC1 6A3 in tumours it 
was upregulated more than 2-fold in 7 tumours. The mean fold-change 
across all 39 turnours was 1.4 (lower and upper quartiles 1.1 and 1.7). A 
paired Mest of the raw data showed significant upregulation (mean control 
signal 520, mean raw signal 690, ratio 1.3, p=0.0003). 
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Figure 4.1 Graphic 
representation of 
array results of in 
vivo hypoxia gene 
expression in 
bladder cancers, for 
all genes induced 
by hypoxia in vitro 
(as listed in Table 
3.1 ). In order of 
Genespring 
'Interest' function 





the top of the list. 
Some of the 32 
genes are 
represented by 
more than one row 
as they were 
represented by 
more than one spot 
on the array eg 
CyclinG2 (CCNG2). 
One columns = One 
tumour sample. 
Samples/columns 
(starting on the left) 
1 to 26 = 
superficial, 
samples/columns 
(on the right) 27-39 
= muscle invasive. 
One row=one gene 
as labelled. Tumour 
cDNA was 
competitively 
hybridised against a 
panel of 11 cancer 
cell lines. Red=2- 
fold or more 
upregulation, green 
= down regulation, 
brown equals no 
change. 
Brightness=statistic 
al trust. Gene 
abbreviations are 

























Figure 4.2 Fold changes of hypoxia-inducible genes based on in vivo array 
data. IGFBP-3 makes the largest fold contribution and is upregulated more 
than 2-fold in the majority of samples. 
47 10 13 16 19 22 25 28 31 34 37 
Tumour number 1-26=superficial 27-39= invasive 
4.2.2 Hypoxia inducible genes downregulated on the in vivo array 
Down regulation on the in vivo data was defined as more than 0.5 fold in 
more than 5 turnours (green in Figure 4.1) in vivo. Of 32 genes upregulated 
by hypoxia in vitro, 24 were downregulated. The most downregulated gene 
in vivo was lactate dehydrogenase. Genes that were upregulated more than 
3-fold by hypoxia, yet were among the top ten of this downregulated group 
were Bcl-2 Binding Protein NIP3 (NIP3), lysyl hydroxylase isoform 2 
(PLOD2) and Aldolase C. 
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4.2.3 Scoring of tumours for necrosis and hypoxia 
To correlate the in vivo transcriptome of these tumours with tumour hypoxia, 
we scored paraffin sections of the tumours using CA IX stain as a marker of 
hypoxia. We also scored tumours for the presence of intratumoural necrosis 
seen with haernatoxylin and eosin stain. 31 tumours were available for both 
scores (Table 4.1). CAIX positive staining was present in 45% of all turnours 
and appeared to be equally prevalent in superficials as in invasives. 
Necrosis became more prevalent with increasing grade and stage. 
Surprisingly only two of seven necrotic invasive turnours (stage T2 or T3) 
stained positive for CA IX, suggesting that a significant proportion of 
invasive bladder cancers do not upregulate CA IX in the perinecrotic 
regions. Overall 71% of bladder tumours had either CA IX staining or 
necrosis. 
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Stage/g rade Total Number CA9 Positive % 
Ta 8 5 63 
Tl /G2 7 4 57 
Tl/G3 6 2 33 
T2/G2 4 2 50 
T2/G3 4 0 0 
T3 4 2 50 
All 33 15 45 
Stage/g rade Total Number Necrosis Positive % 
Ta 7 0 0 
Tl /G2 6 0 0 
Tl/G3 7 1 14 
T2/G2 4 1 25 
T2/G3 4 3 75 
T3 4 3 75 
All 32 8 25 
Stage/g rade Total Number Necrosis and CA9 Positive % 
Ta 7 0 0 
Tl/G2 6 0 0 
Tl/G3 6 0 0 
T2/G2 4 1 25 
T2/G3 4 0 0 
T3 4 1 25 
All 31 2 6 
Stage/g rade Total Number Necrosis and/or CA9 Positive %- 
Ta 7 5 71 
Tl/G2 7 5 71 
Tl/G3 6 3 50 
T2/G2 4 2 50 
T2/G3 4 3 75 
T3 4 4 100 
All 31 22 71 
Table 4.1. Presence of CA IX positive immunohistochemistry and necrosis 
by stage and grade in bladder tumours taken from the 39 tumours used on 
the in vivo genearray. 
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HIFI score 0 1 2 Total 
Ta-Tl 6 9 8 23 
T2-T3 4 6 1 11 
Total 10 15 9 34 
Table 4.2 Presence of HIFla positive immunohistochemistry by stage in 
bladder turnours taken from the 39 tumours used on the in vivo genearray. 
Score 0 means no HIF staining, score 1 and 2 intermediate and strong HIF 
cytoplasmic staining respectively. There was no significant difference 
between the proportion of superficial and invasive bladder cancers staining 











Figure 4.3 Examples of necrosis as seen on haematoxylin and eosin 
staining. A shows gross necrosis score 2/2. B and C show the same area of 
comedo necrosis (magnified in B) necrosis scorel defined as an area 








Figure 4.4 Examples of tissue array staining for CA IX both showing areas 
of intense lattice-like membrane staining. A also demonstrates scattered 
nuclear staining and intense widespread cytoplasmic staining. Stroma did 
not stain fo rCA Ix. 
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4.2.4 Correlation of immunohistochemical CA IX and necrosis scores of 
turnours with fold-upregulation of hypoxia inducible genes from the in vivo 
array data 
Of the eight most upregulated genes on the in vivo array data; IGFBP3, 
VEGF, CCNG2, NDRG1, PFKFB3, RNAse4, Adrenomedullin (ADM) and 
Glucose transporter 1 (GLUT-1), only one gene showed a correlation with 
CA IX scores. None of the gene fold-changes individually or combined all 
together correlated with necrosis or HIR immunohistochemistry scores. 
GLUT-1 fold-changes correlated with CA IX scores (p=0.008 r2 =0.21, 
Figure 4.5) and were significantly higher in CA IX positive tumours (means 
0.9 vs 1.8 p=0.03 2-tailed t-test variances not assumed to be equal). 
GLUT1 fold changes significantly correlated with ADM fold-changes (Figure 
4.5). CA IX itself was not on the genearray to test a correlation with 







.. j 0 





GLUT I fold-changes 
. 21 P=0.008 
=0.23 P=0.003 
Figure 4.5 GLUT-1 fold-changes in vivo correlated with scores for CA IX 
staining of turnours by immunohistochernistry as a surrogate marker of 
hypoxia. ADM fold-changes correlated with GLUT-1 fold-changes. CA IX 
itself was not on the array. 
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234 
CA IX staining score 
1 
4.2.5 Analysis of genes upregulated in CA IX positive tumours 
Having defined which tumours were CA IX positive, it was possible to split 
the tumours into two groups and by performing a two-tailed Mest (variances 
not assumed to be equal) on each gene, and look for genes differentially 
regulated between the two groups. The result for genes with p values <0.25 
is shown in Figure 3.4, Table 3.2. Very few of these genes were 
upregulated in the CA IX group. By performing a Mest 6000 times, by 
chance 0.05% or 300 genes will come up as false positive. So although 
individually there were many significant genes (p<0.05), when the Benjamin 
and Hochberg correction for multiple Mests was performed the p values 
were all >0.05. 
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Table 4.2. (next page) Tabulated results of Figure 4.6. Genes upregulated 
in CA IX positive bladder tumours compared with CA IX negative tumours 
(total n=33). Superficial and invasive tumours included. p value cut off 0.25. 
Non-parametric test. Genes upregulated in CA IX positive tumours are in 
red. 
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Figure 4.6 Genes differentially regulated in CA IX positive bladder turnours 
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4.2.5 Analysis of genes upregulated in necrotic invasive bladder tumours 
Similarly, genes upregulated in necrotic tumours were looked for. Since necrosis 
was a feature only in invasive cancer (bar 1 superficial cancer), to avoid 
confounding differences between different stages of disease, this analysis was 
per-formed only for invasive cancers. Results in Figure 3.5, Table 3.3 again show 
genes with significance values p<0.25. Again, as with CA IX, after correcting for 
multiple Mests, none of the genes show a significant difference (p<0.05). 
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Figure 4.7 Genes 
differentially regulated 
in necrotic invasive 
turnours compared 
with invasive tumours 
with no necrosis. 
Nonparametric test 
with multiple testing 
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4.3 Discussion 
In this chapter 32 hypoxia-upregulated genes in vitro have been were further 
investigated for their role in bladder cancer biology by analyses of in vivo 
array data and in vivo staining for necrosis and hypoxia marker CA IX. 
4.3.1 Hypoxia inducible genes upregulated on the in vivo array 
On the tumour array, 70 of 6000 (1.2%) genes were upregulated more than 
2-fold in over 30 tumours. 3 of these 70 genes (4.3%) were hypoxia-inducible 
on the in vitro array (IGFBP-3, VEGF, CCNG2). Since only 32 of 6000 
(0.53%) genes on the in vitro array were upregulated by hypoxia, hypoxia- 
induced genes are over-represented in the group of genes most upregulated 
on the tumour array (p< 0.01 Ch i2 test). If the 32 hypoxia-induced genes 
were distributed at random we would have expected only 0.53% of 70 i. e. 
less than one gene to appear in this group of 70. Genes upregulated on the 
in vivo array were also the most hypoxia inducible genes on the list (Figure 
4.4) 
IGFBP3 is discussed elsewhere (see chapter 3 and 5) and VEGF is well 
described in bladder cancer, However the in vivo array data here highlighted 
the potential importance of Cyclin G2 in bladder cancer. Cyclin G2 is known 
to be regulated by the VHL/hypoxia pathway (Wykoff, Beasley et al. 2000). It 
is an unconventional cyclin highly expressed in the immune system (spleen 
and thymus) as well as kidney, cerebellum and prostate (Horne, Goolsby et 
al. 1996). It is thought to be a negative regulator of the cell cycle with peak 
expression in S phase. Transfection of Chinese Hampster Ovary (CHO) cells 
and HEK293 fibroblasts with it stimulates apoptosis (Bennin, Don et al. 
2002). In murine B cells expression is upregulated by DNA damaging agents 
(Bates, Rowan et al. 1996) and negative growth factors independent of p53 
(Horne, Donaldson et al. 1997). Cyclin G2 RNA levels have been shown to 
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be significantly expressed at a lower level in stage T2 bladder tumours than 
in Ta by microarray analysis validated by immunohistochemistry on a tissue 
array (Dyrskjot, Thykjaer et al. 2003). Cyclin G2 was also upregulated in Ta 
tumours compared to normal tissue. This contrasts with the result on the 
tumour array here, where there was no significant difference in Cyclin G2 
mRNA fold change from Ta to T2 tumours. 
The top three genes upregulated in vivo were upregulated more than 2-fold 
in more than 30 of 39 turnours each. As 71 % of the turnours on staining had 
some evidence of hypoxia (necrosis or CA IX staining) it is possible that the 
upregulation of these genes is driven by intraturnoural hypoxia. However the 
upregulation seen across all turnours (Figure 4.1) suggests that other factors 
may play a role. 
Oncogenic activation of these genes may occur in bladder cancer via HIF or 
HIF independent mechanisms. Upregulation of HIF-la is known to occur by 
tumour suppressor genes (mutant p53 or PTEN) and oncogenes (H-ras). The 
HER2 oncogene, which overexpresses a tyrosine-kinase domain on the EGIF 
receptor, is one potential candidate as the protein is over expressed in 57% 
of invasive bladder cancers (Latif, Watters et al. 2003; Latif, Watters et al. 
2004) although gene amplification occurs only in 5%. In vivo array data here 
demonstrated HER2 upregulation more than 2-fold in 22 of 39 of the bladder 
tumour samples. Interestingly in an in vitro genearray study of HER2- 
overexpressing breast carcinoma cells the hypoxia inducible genes IGFBP-3 
NDRG1 and P4HA were all upregulated (Mackay, Jones et al. 2003). These 
three genes are clearly hypoxia upregulated in our bladder cancer cell line 
and IGFBP3 and NDRG1 are clearly upregulated on the in vivo array data. In 
vitro data on breast cell lines has shown that overexpressing HER2 
increases expression of HIF-1a and VEGF (Laughner, Taghavi et al. 2001). 
Immunohistochernical staining for HER2 in breast cancer is associated with 
HIF1 staining and high levels of angiogenesis, however HER2 breast 
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cancers only conferred a significantly poorer prognosis if they also stained for 
HIF-let (Giatromanolaki, Koukourakis et al. 2004). If activation of HER2 in 
humans results in overexpression of HIF-1a independently of conditions of 
hypoxia, as occur in experimental studies, this interaction may represent a 
main pathway conferring clinical aggressiveness to HER2 positive bladder 
tumors. 
The across the board upregulaton on these genes on the in vivo array may 
be highlighting gene expression differences between monolayer culture and 
the three-dimensional tumour environment where there are more complex 
influences on gene expression present. Three-dimensional geometry in in 
vitro cell growth alone has been shown to have dramatic influences on gene 
expression profile (Dangles, Lazar et al. 2002) responses of cells to differing 
stimuli and biological function (Mansbridge, Ausserer et al. 1994; Dangles, 
Femenia et al. 1997; Huang and Ingber 1999; Lang, Sharrard et al. 2001). 
Primary tumours have added complexity from angiogenesis, stromal 
interactions and inflammation. 
4.3.2 Hypoxia inducible genes downregulated on the in vivo array 
Of 32 genes upregulated by hypoxia in vitro, 24 were downregulated more 
than 0.5-fold in more than 5 tumour samples (green) on the in vivo array 
(Figure 4.1, Figure 4.4). That this occurred even in tumours where necrosis 
and CA IX staining were present was surprising. LDH-C, NIP3, Aldolase C, 
and PLOD2 were the most downregulated genes. LDH-C is the testis-specific 
member of the family of LDH that is expressed in normal testicular tissue but 
not in other normal tissues. However in cancer and cell lines it has significant 
expression levels in virtually all human tumours tested (Koslowski, Tureci et 
al. 2002). Although bladder cancer was not tested true down regulation of 
LDH-C in bladder cancer is unlikely. LDH A is known to be hypoxically 
regulated, with a gene promoter that contains an essential binding site for 
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HIF (Semenza, Jiang et al. 1996). This raises the question of why these 
genes are downregulated compared to the normoxic cell line panel. The cell 
lines may have basal upregulation of hypoxia-inducible genes in normoxia 
due to oncogenic changes. The in vivo downregulated genes were in fact the 
hypoxically lesser upregulated genes (Table 4.4), so if they were only mildly 
basally upregulated in the cell lines this would obscure their in vivo 
upregulation. 
Aberrant spots on the array could also produce an artifactual result, however 
three of these most downregulated genes were represented by 2 or 3 array 
spots each, so that is unlikely. 
Table 4.4 (next page) Replication of Table 3.1 showing the genes 
upregulated on the in vivo array in red. Genes downregualted on the in vivo 
array are in black. Clearly the genes that are more sensitive to hypoxia 
(greater fold upregualtion near the top of the list) were more likely to be 





hypoxia GENE FUNCTIONAL GROUP 
16 24 
Hours Hours 
Known to be hypoxia-upregulated in other cell lines 
1 3.4 17 Adrenomedullin (ADM) Vascular Tone 
Insulin-like growth factor binding 
2 2.6 12.1 protein 3 (IGFBP-3) Apoptosis 
n-myc downstream regulated 
3 2.9 8.2 protein 1 (NDRG1) Cell Cycle 
4 5.3 6.6 BCL2 binding protein NIP3 (NIP3) Apoptosis 
Inducible 6-phosphofructo-2- 
5 2.7 4.7 kinase (PFKFB3) Glucose Metabolism 
6 2.4 4.7 Lysyl Hydroxylase (PLOD2) Tissue remodeling 
7 2.2 4.4 MAX interacting protein 1 (MAX 1) Transcription factor 
8 3.1 4.2 Glucose Transporter 1 (GLUT 1) Glucose metabolism 
1,4-Alpha Glucan Branching 
9 2.3 3.9 Enzyme (HGBE) Glucose Metabolism 
10 2.2 3.8 Cyclin G2 (CCNG2) Cell Cycle 
11 2.5 3.7 Proline-4-hydroxylase (P4HA1) Oxygen sensing/ECMM 
12 3.2 3.2 Adenylate Kinase 4 Nucleotide metabolism 
13 2.9 3.1 Aldolase C (ALDO C) Glucose Metabolism 
14 1.9 3 Prolyl-4-hydroxylase alpha subunit Oxygen sensing 
15 1.8 2.6 Haem oxygenase 1 (HMOX1) Vascular Tone 
16 2.5 2.5 EGL9 Homologue 1 Oxygen sensing 
Testis-specific lactate 
17 2.1 2.5 dehydrogenase (LDH C) Acid Base 
18 1.9 2.5 VEGF Angiogenesis 
19 2.4 2.5 Adenylate Kinase 3 (AK3) Nucleotide metabolism 
Dual Specificity Phosphatase 1 
20 1.7 2.4 (DUSP1/CL100/MKP1) Cell signalling 
21 1.7 2.1 DEC 1 Differentaition 
Glucose-6-Phosphate isomerase 
22 2.6 2.1 (GP! ) Glucose Metabolism 
23 2.1 2.1 Fructose-Bisphosphate Aldolase A Glucose Metabolism 
Not previously known to be hypoxia regulable 
Solute carrier family 16 member 3 
24 2.8 8.2 (SLC16A3) Acid Base 
Preferentailly expressed antigen 
25 4.5 4.9 of melanoma (PRAME) Antigen 
26 2.8 4.1 Importin Beta 3 Nuclear pore protein 
27 1.9 3.1 RNAse 4 Antimicrobial/? Angiogenic 
28 2.2 2.9 Protooncogene ABL1 Cell cycle 
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ESTs 
29 3 3.9 50378_A EST 
30 3.2 3.3 50022_A EST 
31 3.5 3.3 31564_B EST 
32 2.1 2.4 21875 A EST 
Table 4.4 (above) Replication of Table 3.1 showing the genes upregulated on 
the in vivo array in red. Genes downregualted on the in vivo array are in 
black. Clearly the genes that are more sensitive to hypoxia (greater fold 
upregualtion near the top of the list) were more likely to be upregulated on 
the in vivo array. 
4.3.3 Correlation of immunohistochemical CA IX and necrosis scores of 
tumours with fold-upregulation of hypoxia inducible genes from the in vivo 
array data 
GLUT1 and showed a significant correlation with CA IX score as a surrogate 
marker of hypoxia. GLUT1 and ADM also showed significant correlation with 
each other. GLUT 1 protein immunohistochemistry has previously been 
shown to correlate with CA IX staining in cervical cancer and, like CA IX, has 
been shown to be a marker of tumour hypoxia (Airley, Loncaster et al. 2001; 
Airley, Loncaster et al. 2003). The correlation here shows that the same is 
likely also to be true for RNA transcripts in bladder cancer. ADM, a secreted 
protein, may also prove to be useful as a marker of hypoxic tumours in the 
urine. The other genes did not correlate with tumour hypoxia and necrosis 
scores and were upregulated in many more turnours. This was surprising as 
we previously showed that VEGF protein staining correlated with 
CA IX 
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staining in bladder cancer (Turner, Crew et aL 2002). We might have 
expected all 8 genes significantly upregulated by hypoxia in vitro and in vivo 
to correlate with tumour scores of hypoxia and necrosis in vivo. However as 
discussed in 4.3.1 oncogenic changes specific to bladder cancer, but not 
found in the majority of the cell line panel, may contribute; as well as the 
complex gene expression difference between monolayer cell culture and the 
three-dimensional tumour environment: In particular the lack of blood 
vessels, stromal interactions and inflammation in monolayer cell culture. 
These results show that there is significant concordance of genes induced by 
hypoxia in vitro and in vivo in spite of differences in tissue complexity and 
that there is concordance in vivo for a subset of hypoxia-induced genes 
(ADM, GLUT1 and CA IX protein), which may provide a hypoxia signature for 
analysis of gene array data. Hypoxia-regulated genes are disproportionately 
upregulated in primary bladder cancer. The induction of putative pro- 
apoptotic, cell cycle arrest pathways commonly occurs (IGFBP-3 and 
CCNG2) as well as angiogenic pathways (VEGF). Many hypoxia-induced 
genes (NIP3, PLOD2, Aldolase C) appear downregulated in vivo but this may 
be due to basal upregulation in cancer cell lines. 
4.3.4 Addendum to Chapter Four added June 2008: 
Since working on this thesis there has been a recent publication on 
identifying hypoxia regulated genes on in vivo cancer samples. In agreement 
with Chapter Four in this thesis, they found that grouping tumours according 
to immunohistochernical CA IX and HIF 1 staining was not fruitful in 
identifying known hypoxia related genes. However by clustering genes 
around a group of 10 well characterised hypoxia regulated genes in vitro, 99 
correlated genes were identified 27% of which were known to be hypoxia 
regulated from the literature (validating the method). Furthermore on 
multivariate analysis this cluster of 99 genes was found to have independent 
prognostic value in 59 head and neck cancers (RR 1.96 Cl 1.16 to 3.33) with 
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16 months follow-up and in 245 breast cancers (RR 1 . 38 Cl 1.11 to 1 . 70) 
with 7 years follow-up. Pearson correlation was used within the framework of 
Significance Analysis of Microarrays (SAM). Genes were considered 
significantly correlated to the core of 10 genes if they appeared in more than 
50% of the clusters. (Winter, Buffa et al. 2007). 
Subsequent to this paper Moller-Levet has robustly described a new form of 
statistical analysis called Enhanced correlation, which outperforms Pearson 
correlation for microarray data. Essentially this method exploits the 
information from biological samples more efficiently by first calculating inter- 
sample similarities within a dataset and then integrating this additional 




Measurement of IGFBP-3 and Angiogenin protein in 
the urine of bladder cancer patients, measurement of 
IGFBP-3 in cell culture supernatants, and in vitro 
viability of bladder cancer cell line RT112 and HUVE 
cells under hypoxia 
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5.1 Introduction 
The results of the preceding two chapters confirmed that mRNA for IGFBP3 
and RNAse4 was induced by hypoxia in all bladder cancer cell lines tested 
and in normal urothelium. This chapter concentrates on the measurement of 
protein. Since IGFBP3 is a secreted protein, levels for it were assessed in 
the urine of bladder cancer patients. RNAse4 protein may also be secreted 
however no commercially available ELISA for it exists. However it shares 
similar 5'untranslated region on its mRNA with the secreted protein 
Angiogenin with implications for the similar transcriptional control. 
Angiogenin like RNAse4, is an RNAse that has been described as hypoxia 
inducible in other cell lines. It seemed likely therefore that Angiogenin protein 
would also be upregulated in the urine of bladder cancer patients. 
Furthermore a commercial ELISA did exist for Angiogenin. Levels of IGFBP3 
protein were also measured in cell culture supernatant of RT1 12 cells as this 
cell line had showed the greatest fold upregulation of its mRNA (38-fold). 
HUVEC cells were also examined as an example of an untransformed cell 
line in which upregulation of IGFBP3 mRNA had also been confirmed (7- 
fold). In case of any confounding effect of cell death under hypoxia the cell 




5.2.1 Validation of the IGFBP3 ELISA on urine 
In order to ensure that urine was not affecting the recovery of IGFBP3 
protein by ELISA, neat IGFBP3 protein was added to deionised water, cell 
media and urine (Figure 5.1). The fetal calf serum in the cell media may 
have contained IGFBP3, which would account for the small rise above 
baseline. The urine contained approximately 20 ng/ml IGFBP3 and recovery 
paralleled that seen in deionised water. 
. R., emovery of IGFBP3 protein by 
ELISA 
C CO) 0 CL 
LL 0 
-2 
Concentration of IGFBP3 added 
ng/ml 
Figure 5.1 Recovery of IGFBP3 proteins by ELISA. 
m Urine 
Media plus 10%serum 
Deionised water 
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5.2.2 Levels of lGFBP3 in the urine of bladder cancer patients 
lGFBP-3 at the transcript level was upregulated higher and more frequently 
than VEGF in both in vitro and in vivo arrays. We therefore measured levels 
of IGFBP-3 protein in the urine (Figure 5.2). Urine from 157 bladder cancer 
patients and controls was collected prospectively and IGFBP-3 levels 
measured by ELISA. There was a significant increase in urinary IGFBP-3 
concentration from control/clear groups to superficial cancers to invasive 
cancers, p<0.01 for superficial vs. control/clear, p<0.01 for invasive vs. 
control/clear [IGFBP-3 ng/ml mean (standard deviation); controls 15.2ng/ml 
(7.55); clears 14.6ng/ml (8.1); superficial 27.7ng/ml (29); invasive 55.1ng/ml 
(40)]. After correction for urinary creatinine significance (p<0.01) was 
retained for invasive turnours, but not for the superficial group. There were 
15 stage T1G3 tumours in the superficial group. There was no significant 
difference between levels in the urine of T1G3 tumours and other superficial 
tumours or with the invasive group. If a single exceptionally high (>4 
standard deviations) level in the superficial group is excluded the mean 
corrected levels of urine IGFBP-3 increase with stage and grade; superficial 
stage T1 G2 or lower, 351 ng/mmol Cr; superficial stage T1 G3,479 ng/mmol 
Cr; invasive stage T2-T4,733 ng/mmol Cr. 
One of the anonymously taken medical student controls had a level of 
IGFBP-3 five standard deviations higher than the rest of this group. Despite 
this the significant difference between this group and the bladder cancer 
group held. All medical student control urines dipped negative for blood so an 
undiagnosed cancer is unlikely in such a young person. The likely 













.0 < lo 
0 
LL a 
= No tumou r age< 30 n= 17 
** 
Figure 5.2 Levels of IGFBP-3 in urine: TOP absolute level, BOTTOM 
corrected level for urine creatinine. Invasive significantly higher than all 
control groups in both cases. Superficial significantly higher than control 
groups for absolute levels only. (**=p<0.01). Error bar = standard error. 
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5.2.3 Levels of Angiogenin in the urine of bladder cancer patients 
A smaller number of the urines were tested for Angiogenin (Figure 5.3). 
There were 17 controls <30 yrs, 12 aged >30 yrs, 12 patients who 
previously had bladder cancer but were currently clear at check flexible 
cystoscopy, 12 superficial and 17 invasive cancers. Invasive cancers had 
significantly (p<0.001) higher absolute and corrected levels in their urine 
than the three control groups. Invasive cancers also showed significantly 
higher levels than superficial cancers in the absolute levels only. One 
patient in the superficial cancer group had a very high level, which makes 
the mean and standard error for this group large. For absolute levels 
superficial cancer was significantly higher than controls >30yrs (p=0.045) 
and significantly lower than invasive (p=0.04), with a trend to higher values 
than controls <30yrs or clears (p=0.05 and p=0.06 respectively). Corrected 
levels did not show a significant difference between superficials and 


















<30yrs >30 yrs Clear T1G3 Invasive 
EI3 <30 yrs n= 17 
E3 >30 yrs n= 12 
M Clear n= 12 
M Tl G3 n=12 
F=: ý Invasive n=21 
Figure 5.3 Levels of Angiogenin in urine: BOTTOM absolute level, TOP 
corrected level for urine creatinine. Invasive significantly higher than all 
control groups in both cases (**=p<0.01). T1G3 significantly higher than 
control group (>30 yrs old) for absolute levels only (p=0.04). Error bar = 
standard error. 
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5.2.4 Levels of lGFBP3 protein in cell culture supernatant of RT1 12 cells 















0 normoxia, control 
0 hypoxia 42 or 72 hours 
Figure 5.4 Concentration of lGFBP3 in cell culture supernatant of 
untransformed human umbilical vein cells (HUVE) and bladder cancer cell 
line RT1 12 at normoxia and 48 and 72 hours hypoxia (0.1 % oxygen). The 
normoxic and hypoxic levels of IGFBP3 in HUVE supernatant was 
significantly smaller than that found in RT1 12. Both cell types were seeded 
at 5000 cells per well making a difference in confluence status unlikely as 
an explanation. In both cell lines the protein showed a trend to upregulation 
by hypoxia and for RT1 12 at 72 hours this difference was statistically 
significant (*=P<0.05, error bar =1 standard deviation, 3 replicates for each 
bar). 
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HUVE 48 hours HUVE 72 hours RT1 12 48 RT112 72 
hours hours 











0 HUVE 48 hours 
= HUVE 72 hours 
-A--RT112 48 hours 
---X--RT112 72 hours 
Hypoxia 
Figure 5.5 Percentage survival of HUVE cells and RT1 12 cells under 
hypoxia (0.1 % oxygen) compared to normoxic controls seeded at the same 
number per well and grown for the same time under normoxia. Viability was 
measured using the MTS assay by light absorbance at 490nm. RT1 12 cells 
grew as well under hypoxia as normoxia whereas HUVE cells grew 




The finding of raised IGFBP-3 in the urine of bladder cancer patients has not 
been previously noted. In prostate cancer, levels have been shown to be 
significantly lower in the plasma of patients than in controls (Zhao, Grossman 
et al. 2003). In vitro experiments on cell growth and IGFBP-3 make it likely 
that the levels of IGFBP-3 seen here in urine are of clinical significance. 
Levels as low as 1 Ong/ml and more commonly 30-50 ng/ml have been shown 
to have inhibitory effects on growth of neoplastic cells in vitro. (Martin and 
Baxter 1999; Ewton, Kansra et al. 2002). Significantly elevated levels in the 
urine have also been described in interstitial cystitis, with levels in bacterial 
cystitis lower than this. However the mean absolute level in interstitial cystitis 
is lower than seen in these cancer patients with greater overlap with controls 
(mean level in interstitial cystitis 13.2ng/ml) (Keay, Zhang et al. 1997). It must 
also be noted that the ELISA measures both proteolysed fragments and 
intact IGFBP-3 (Diamandi, Mistry et al. 2000). The rise we measured may 
reflect increased proteolysis of IGFBP-3 that would make more IGF available 
to the tumour. However the data suggests at least that direct upregulation of 
mRNA levels of IGFBP-3 occur with or without increased proteolysis. 
If IGFBP3 were acting predominantly as an apoptotic factor in bladder 
cancer, significantly raised levels would be expected in higher stages and 
grades where apoptosis is more common. In transitional cell cancer of the 
bladder levels of apoptosis, as assessed by light microscopy, correlate with 
increased stage, grade and markers of proliferation (Ki-67). However 
apoptosis has no useful independent prognostic value over stage and grade 
on multivariate analysis (Lipponen and Aaltomaa 1994). 
As a screening tool for bladder cancer urinary IGFBP-3 lacks the sensitivity 
of a direct cystoscopy and a significant number of cancer patients had 
values similar to age-matched controls. This may be because small tumours 
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of low grade secrete less protein, which is the likely problem with many 
bladder tumour markers (Boman, Hedelin et al. 2002). 
Raised levels of angiogenin were also found in the urine of bladder cancer 
patients. Specifically, like IGFBP3, very significantly raised levels were found 
in invasive turnours. This would fit with the increased levels of angiogenesis 
that are found in invasive turnours where high levels of angiogenesis have 
been related independently to prognosis. The connection between 
angiogenin and RNAse4 has already been discussed in Chapter 3. 
Significant levels of IGFBP3 were measured in the supernatant of bladder 
cancer cell line RT1 12 even in normoxia raising the possibility that levels of 
lGFBP3 found in the urine of bladder cancer patients may not be related to 
levels of hypoxia in the tumour. However even this high level in vitro was 
increased 150% by hypoxia. The untransformed HUVE cells secreted 
significantly less IGFBP3 in normoxia and hypoxia than RT1 12 
Cell viability under hypoxia was interestingly not affected in the RT1 12 
cancer cell line even after 72 hours and despite the upregulation of IGFBP3, 
which is a likely apoptotic factor. This suggests either that RT1 12 proliferates 
so fast that it outpaces any increased apoptotic rate stimulated by the 
increased lGFBP3 or that this cell line has molecular pathways to avoid any 
apoptotic effects of IGFBP3. 
HUVE cells significantly lost viability in hypoxia. Ideally normal urothelia 
would have been used in this experiment but supplies were limited. In some 
senses this loss of viability in these untransformed cells under hypoxia is 
surprising as previous study (Graeber, Osmanian et al. 1996) in 
untransformed cells (mouse embryonic fibroblasts) suggested that they 
maintain viability in hypoxia at 48 hours. However that same study found that 
mouse embryonic fibroblasts transformed by adenovirus early region 1A 
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(ElA) and activated Ha-ras dramatically enhanced their susceptibility to 
apoptosis under hypoxia. Although these HUVE cells were not transformed, 
they were stimulated to growth by exogenously applied epidermal cell growth 
stimulant (ECGS) for the duration of the experiment, and this stimulation 
could have rendered them more susceptible to hypoxia induced apoptosis. 
Physiological data from healing wounds strongly suggests that apoptosis 
occurs more readily in cells that are activated to proliferate rather than in 
quiescent cells (Kane and Greenhalgh 2000; Takahashi, Aoshiba et al. 2002; 
Akasaka, Ono et al. 2004). Clinically, wounds that are ischaernic or infected 
are well known not to heal and this maybe due to increased rates of 
apoptosis caused by oxidative stress and/or hypoxia. Recent in vitro 
investigation of wound healing in normal human urothelial cells in the United 
Kingdom (Varley, Hill et al. 2005) has found that whereas normal human 
urothelial cells are mitotically quiescent and GO arrested in situ, they rapidly 
enter the cell cycle upon seeding in primary culture and show reversible 
growth arrest at confluence. Growth was propagated in the absence of 
exogenous epidermal growth factor, but autocrine signaling through HER-1 
via the MAPK and P13-kinase pathways was essential for normal 
proliferation and migration during urothelial wound repair. 
The role of lGFBP3 could be further tested by the use of lGFBP3 blocking 
antibodies (Kamanga-Sollo, Pampusch et al. 2005) or the technique of RNAi 
to IGFBP3, and the addition of IGF I and 11. 
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Chapter Six 
An investigation into the prognostic significance of 





The purpose of this chapter was to investigate hypoxia and necrosis in high 
grade and invasive bladder cancer and to relate this to prognosis. The study 
method used was immunohistochernistry of 98 primary cystectomy 
specimens stained and scored for necrosis, and a range of hypoxia- 
associated markers ; Carbonic anhydrase IX (CA IX), Hypoxia-inducible 
factor la ( HIF& ), HIR2 andBcl2/adenovirus EIB 19kD-interacting 
protein 3 (NIP3). The advantage of using cystectomy specimens is that they 
are more accurately staged than endoscopically resected tumours, which are 
inaccurately staged in 40% of cases (Dutta, Smith et al. 2001). 
Cystectomy studies large enough to conduct multivariate analysis of 
prognostic factors in invasive bladder cancer universally agree that stage and 
nodal status are independent prognostic factors (Bassi, Ferrante et al. 1999; 
Bella, Stitt et al. 2003; Frank, Cheville et al. 2003; Stein, Cai et al. 2003). 
Tumour size in T2 cancer (Cheng, Neumann et al. 1999); blood vessel 
invasion (Leissner, Koeppen et al. 2003); nonTCC non SCC subtype 
(Rogers, Palapattu et al. 2006); and microvessel density as a measure of 
angiogenesis have also been shown to be independent prognostic indicators. 
Angiogenesis is highly associated with the presence of lymph node 
metastasis (Jaeger, Weidner et al. 1995) (Bochner, Cote et al. 1995). 
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Patients who develop metastasis do so at a mean of 11 months from 
diagnosis (Babaian, Johnson et al. 1980). Therefore it was important that 
patients in this study had an average follow-up of at least 11 months. 
At the outset of this thesis there were no other studies on necrosis and HIF- 
1a in transitional cell carcinoma of the bladder. Since completion one group 
has published two papers on HIF-1a in bladder cancer and there have been 
three large studies on necrosis three other types of cancer (transitional cell 
cancer of the upper renal tract, renal cell carcinoma and sarcoma). These 
studies are described in the discussion at the end of this chapter. 
HIF-la has been described in the introduction to this thesis. Any 
upregulation of HIF-1 a in bladder cancer could occur by oxygen-dependent 
(i. e. in perinecrotic or hypoxic areas) or by oxygen-independent means. 
Growth factors, cytokines and other signaling molecules stimulate HIF-1a 
synthesis in a cell-type-specific manner. HIF-lu protein is likely to be 
particularly sensitive to changes in the rate of synthesis because of its 
extremely short half-life under non-hypoxic conditions. Many genetic 
changes, which are known to increase HlFlcc synthesis, occur in bladder 
cancer. 50% of invasive bladder cancers have p53 mutation, 30% have lost 
PTEN, and up to 45% have H-ras mutation. 49% also stain strongly for EGF 
receptor (EGFR) (Neal, Sharples et al. 1990; Brandau and Bohle 2001). 
Autocrine growth stimulation involving HIFlet may also occur in bladder 
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cancer since HlFlcc transcriptionally activates transforming growth factor 
a (TGF a) which binds to EGFR. 
HIF2a is a protein that can also dimerise with HIF-1p. Experiments in control 
and hypoxic rats showed that HIF2a, like HIFIla was induced by hypoxia in 
all organs investigated. In some organs induction of HIF2a was exclusively 
nonparenchymal (kidney) but predominantly parenchymal in others (liver and 
intestine) (Wiesener, Jurgensen et al. 2003). In many tumors including 
bladder, HIF2cc staining is predominantly in tumor-associated macrophages 
(Talks, Turley et al. 2000; Onita, Ji et al. 2002). 
NIP3 is a cell death protein (Ray, Chen et al. 2000) regulated by HIF la 




98 cases were analysed histopathologically. Mean age at cystectomy was 
69.2 years. Two cases were squamous cell histology, the rest transitional 
cell. Only one patient had neoadjuvant chemotherapy. There were 18 stage 
TOM 1 20 T2) 46 T3, and 14 T4. Initial statistical analysis was by the chi test to 
look for associations between markers and pathological stage, grade and 
nodal status. 
Clinical follow-up data was available in 96. There were 5 operative deaths 
within 30 days of surgery, these cases were excluded from survival 
analysis, as it is not known whether they would have died from cancer or 
not. 91 cases were therefore available for survival analysis. Median follow- 
up was 22 months (interquartile range 8-35). There were 18 stage TOM, 19 
T2,42 T3, and 12 T4. The prevalence of necrosis in bladder cancer was 
high and increased with stage (TO-1 17%, T2 30%, T3 66%, T4 67%). 
152 
6.2.1 Results: Chi test analysis of staining associations between necrosis, 
HIFla, HIF2cc, CA IX, NIP3 
Necrosis occurred in small (defined as less than 5mm) islands of comedo 
necrosis and in larger areas of gross necrosis (defined as larger than 5mm). 
HIFla staining was cytoplasmic and in a very few intense cases both 
cytoplasmic and nuclear. CA IX staining was largely cytoplasmic but also 
membranous. HIF2a staining was predominantly in tumor associated 
stromal cells previously identified largely as macrophages. Bcl2/adenovirus 
ElB 190-interacting protein 3 (NIP3) staining was cytoplasmic. (Figures 
6.1,6.2,6.3,6.4) 
Necrosis showed a significant association with higher stage disease and 
positive nodes. CA IX showed a significant association with higher stage 
disease and positive nodes. There was no association between HIF la and 
stage or grade or nodal status. HIF2a also showed no association with stage 
or grade or nodal status. NIP3 showed a significant association with higher 
stage and (paradoxically) with lower grade. CAIX and HIFla were 
significantly associated with necrosis. HIF 2cc and NIP3 were not. None of 
the immunohistochernical markers were significantly associated with HIFUC. 
(Tables 6.1,6.2,6.3,6.4,6.5,6.6,6.7) 
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Figure 6.1 Haernatoxylin and eosin staining of necrotic areas seen in 
transitional cell carcinoma of the bladder whole sections. 
A gross necrosis score 2, x20 
B comedo necrosis score 1, x20 






(Comedo or gross) 
p-value 
Total No. 47 51 chitest 
Stage: 0.0001*** 
TO-1 15 3 
T2 14 6 
T3 14 32 




Nodal status: 0.016* 
Neg. 46 41 
- Pos. 10 
Cancer specific survival_ lo 
0 vs 1/2 0.01* 
0 vs 1 vs 2 0.0001*** 
Table 6.1 Association between necrosis and stage, grade, nodal status, 
clinical follow-up (univariate analysis). Necrosis showed a significant 
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Figure 6.2 CA IX staining of bladder tissue array, x20 
A Score 1 
B Score 2 
C Score 3 
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C 
CA IX negative 
(CA IX score = 
0) 
CA IX positive 
(CA IX score = 
123) 
p-value 
Total: 55 43 
Stage: 0.01* 
TO-1 14 4 
T2 14 6 
T3 18 28 
T4 9 5 
Grade: 
11 6 11 0.06 
111 49 32 
Nodal status: 
Neg. 52 35 0.046* 




Table 6.2 Association between CA IX and stage, grade and nodal status, 
clinical follow-up (univariate analysis). CA IX showed a significant 
association with higher stage disease and positive nodes. 
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Figure 6.3 HIF-1 cc staining x20 
A, B Control cell line transfected with HIF-1a 
A no primary antibody applied (negative control) 
B primary antibody applied (positive control) 
C, D, E, F Bladder tissue array: 
C Score 1 
D Score 2 
E Score 3 with area of necrosis (n) and nuclear staining (nuc) 
F Score 3, no necrosis associated, invasion of muscularis propria 
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HIF 1 negative 
(HIF 1 score 
0-1) 
HIF 1 positive 
(HIF 1 score 2- 
3) 
p-value 
Total No. 47 51 
chi test 
Stage: 0.8 
TO-1 9 9 
T2 10 10 
T3 23 23 





Neg. 43 44 0.4 





HIN score 0-1 vs 2-3 0.13 
HIF1 score 012 vs 3 0.049* 
Table 6.3 Association between HIF 1ccand stage, grade and nodal status, 
clinical follow-up (univariate analysis). HIF 1a showed no association with 
stage nor grade nor nodal status. 
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Figure 6.4 HIF 2cx staining, x20. 
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A Positive control, clear cell renal cell carcinoma with an area of necrosis. 
B, C, D Bladder tumour cores: 
B Score 1 
C Score 2 
D Score 3 
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HIF2a negative 
(HIF2a max 0- 
1) 
HIF2a positive 
(HIF2a max 2- 
3) 
p-value 
Tota INo. 69 29 
Stage: 
TO-1 12 6 0.57 
T2 13 7 
T3 32 14 





111 60 21 
Nodal status: 
Neg. 60 27 0.37 




Table 6.4 Association between HIF2a and stage, grade and nodal status and 
follow-up (Univariate analysis). HIF2cc showed no association with stage nor 
grade nor nodal status. 
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Figure 6.5 Staining for NIP3, x20. 
A Score 1 
B Score 1 
C Score 3 





(NIP max = 0-1) 
NIP positive 
(NIP max 2-3) 
p-value 
Total No. 42 56 
Stage: 
TO-1 13 5 0.03* 
T2 7 13 
T3 15 31 
T4 7 7 
Grade: 
11 3 14 0.02* 
111 39 42 
Nodal status: 
Neg. 37 50 0.9 




Table 6.5 Association between NIP3 and stage, grade, nodal status and 
follow-up. ' Fischer's Exact test. NIP3 showed a significant association with 










Total No. 47 51 
CA IX 0.0003*** 
0 37 22 
1-2-3 10 29 
HIF la 0.0047** 
0-1 30 18 
2-3 17 33 
HIF la 0.28 
0-1-2 43 43 
3 4 8 
HIF 2a 0.4 
0-1 35 34 
2-3 12 17 
NIP 3 0.17 
0-1 24 33 
2-3 23 18 
Table 6.6 Association between immunohistochemical markers and necrosis. 
CAIX and HIFla (when split by the median score) were significantly 
associated with necrosis. HIF 2a and NIP3 were not. 
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6.2.7 Association of markers to H IF 1a 
HIF la score p-value 
0-1 2-3 
Total No. 47 51 
CA IX 
0 29 26 0.29 
1-2-3 18 25 
HIF 2a 
0-1 33 36 0.96 
2-3 14 15 
NIP 3 
0-1 23 17 0.11 
2-3 24 34 
Table 6.7 Association of immunohistochemical markers to HIFla 
immunohistochemistry. None of the immunohistochemical markers were 
significantly associated with HIR a 
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6.2.2 Results: Survival analysis: Necrosis, HIFla, HIF2a, CA IX, NIP3 
Stage (p<0.0001), necrosis (p<0.0001) and HIF la (intensity score 3) 
(p=0.048) were the only significant prognostic factors on univariate analysis. 
Stage (p<0.001 HR 3.29 95% Cl 1.80 - 6.04) and necrosis (p=0.04, HR 
1.92 95% Cl 1.05 - 3.51) were independent prognostic factors on 
multivariate analysis; HIF Ila just lost significance (p=0.07 HR 1.36 Cl 0.98 
- 1.88). Node status and grade were not prognostic factors possibly due to 
the low rate of node reporting (45%) and the small proportion of grade 2 














Graph 6.1 Kaplan Meyer plot of cancer specific survival by stage 
Hazard Ratio SE P-value 95% Cl 
Stage 3.29 1.02 <0.001 1.80-6.04 
Necrosis 
(0 vs. 1 vs. 2) 
1.92 0.59 0.04 1.05-3.51 
HIP (0,1,2 vs 1.36 0.23 0.07 0.98-1.88 
Table 6.8 Multivariate cancer specific survival analysis (SE Standard Error, 
Cl Confidence Interval) 
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-J-0 None n=46 
11 Comedo n=32 
2 Gross n= 13 
P<0.0001*** 
Graph 6.2 Kaplan Meyer plot of cancer specific survival by amount of 
necrosis Univariate analysis. See table 6.9 below 






TO 3 2 1 0 
Tl 15 13 1 (7%) 
T2 19 13 4(21%) 2(10%) 
T3 42 14 21(50%) 7(16%) 
T4 12 4 5(42%) 3 (25%) 
Totals 91 46 32 13 
Table 6.9 Breakdown of the stages and amount of necrosis in the 91 cases 
with clinical follow up used to construct survival Graph 6.2 
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Graph 6.3.2 Kaplan Meyer plot of cancer specific survival, HIR a 
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Graph 6.4 Kaplan Meyer plot of cancer specific survival for CA IX 
170 







-J- Negative/Weak n=69 
I Moderate/Strong n=29 
p=0.057 
Graph 6.5 Kaplan Meyer plot of cancer specific survival for HIF2ot 
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Graph 6.6 Kaplan Meyer plot of cancer specific survival for NIP3 
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6.3 Discussion 
In this study only transitional cell bladder tumors from primary cystectomies 
rather than transurethral resected specimens were used to ensure accurate 
staging (Dutta, Smith et al. 2001). None had previously had radiotherapy. A 
median follow-up of 22 months ensured that most patients who were going to 
develop metastasis had done so by the time of analysis. 
The results show that although hypoxia related factors CA IX and HlFlcc 
were significantly associated with necrosis, the presence of necrosis itself 
was the independent prognostic factor. Areas of necrosis are thought to 
represent areas of chronic severe hypoxia, so this study supports the 
assertion that the development of chronic severe hypoxia in bladder cancer 
is independently associated with a worse prognosis. Hypoxia associated 
markers CA IX and HIFla were not associated with a worse prognosis but 
were significantly associated with necrosis. 
This study demonstrates the high prevalence of necrosis in bladder cancer, 
and suggests that necrosis is an independent prognostic factor. Since this 
study was completed three larger in studies in other cancers have shown 
necrosis to have independent prognostic value (Table 6.10). The results in 
transitional cell cancer of the upper renal tract are of particular relevance and 
show good concordance with the present study's results. In that study, similar 
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to the present study, they also found a relationship between the amount of 
necrosis and progressively worse prognosis. Instead of comedo and gross 
necrosis they defined 'focal' and 'extensive' necrosis. 
Cancer n Median Definition of % with Multivariate analysis 
type Follow-up necrosis necrosis 
years P 95% CI RR 
value 
1 
Upper tract 268 5 Serniquantitative 42% 0.02 1.09-3.05 1.8 
transitional microscopic 
cell on low 
carcinoma' magnification of 
available blocks. 
Focal = <10% 
tumour area, 
Extensive = 
> 10% tumour 
area. 
Clear cell 485 4.2 Macroscopically 27% 0.004 1.36-4.89 2.58 









Sarcoma 3 338 7 Microscopic 57% 0.01 1.2-3.0 1.9 
present or 
absent. 
No 10% cut off. 
Table 6.10 Studies showing necrosis to be an independent prognostic risk 
factor in solid turnours to date (July 2007). Studies l(Langner, Hutterer et al. 
23 2006), (Lee, Byun et al. 2006), (Engellau, Anderson et al. 2004) 
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In bladder cancer a single study to date has found HIFla to be an 
independent prognostic indicator (p=0.02) and associated with microvessel 
density (p<0.001) (Theocloropoulos, Lazaris et al. 2004). However this study 
comprised only 93 predominantly endoscopically resected tumours that may 
have been inaccurately staged, and did not study necrosis. Furthermore one 
year after this study the same group published a larger study (n=140) in 
superficial cancer showing that HIP cc positivity on its own was not an 
independent prognostic factor, but was only when present with p53 positivity 
(Theocloropoulos, Lazaris et al. 2005). This study supports the hypothesis 
that cells with mutations that enable survival in areas of chronic hypoxia are 
more biologically aggressive. 
This was a retrospective study with the potential for selection bias. Six 
different surgeons performed at three different sites, with potential for 
individual variation in case selection and lymphadenectomy. The number of 
nodes removed and whether positive or negative is known to be an 
independent prognostic factor in multiple other large studies, but this was not 
found in this study. However nodal status was reported in only 41 of 91 
patients and statistical analysis was performed assuming the remaining 50 
were node negative. It is therefore more accurate to say that this study 
cannot comment on node status as a prognostic factor. Only after the period 
from which this cohort was taken (1999-2003) was the importance of pelvic 
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lymphadenectomy in bladder cancer shown convincingly in large studies 
(Konety, Joslyn et al. 2003) and has been more routinely performed since 
2003. 
Tumour adaptation and/or clonal selection might explain why necrosis is an 
independent prognostic risk factor (giving more information than stage 
alone). Adaptation to a hypoxic environment occurs with for example the 
secretion of angiogenic factors and upregulation of HIFlain perinecrotic 
areas. Such changes are associated with a more aggressive phenotype. 
However hypoxia severe enough to cause necrosis may also result in 
selection of cells resistant to hypoxic cell death for example p53 mutants and 
this effect has been demonstrated convincingly in vitro (Graeber, Osmanian 
et al. 1996). This effect may explain why p53 mutants are common in 
invasive cancer where necrosis is common but rare in superficial bladder 
cancer where necrosis rare. The exception being CIS where presumably the 
initiating event is a de novo p53 mutation. 
HIFla staining was significantly associated with areas of necrosis but a 
significant minority (3/12 or 25%) of strongly HIFIla positive tumors were 
completely negative for necrosis and CA IX staining. In these tumors HIFla 
may be predominantly under oxygen-independent regulation by growth 
factors and oncogenes. Indeed it has been shown since this thesis was 
started that bladder cancer cell line EJ when transfected with HIF1 and 
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grown as xenografts in nude mice, form tumours of a similar size but with 
less necrosis and greater microvessel density compared to vector-only 
transfected controls (Kondo, Hamada et al. 2005). Both hepatoma and renal 
cell carcinoma cell xenografts grow larger and with more blood vessels when 
transfected with HIF1 (Kondo, Hamada et al. 2005) (Maxwell, Dachs et al. 
1997). 
HlF1cc has been proposed as a target for therapy (Giaccia, Siim et al. 2003). 
The effects of antagonising HIFlot in vivo are unknown. HIFla upregulation 
by hypoxia in untransformed cells in vitro causes cell cycle arrest (Goda, 
Ryan et al. 2003) (Carmeliet, Dor et al. 1998) inhibiting proliferation and 
apoptosis. Antagonising HIFla in cancer may cause cancer cells in hypoxic 
areas that have been made quiescent by HIF la to re-enter the cell cycle or 
to apoptose. Cells re-entering the cell cycle would be more prone to 
chemotherapy or radiotherapy. 
Tumors with HIF2cc staining showed a trend to a better prognosis (p=0.05) 
and did not show any association with necrosis. This is in contrast to another 
study (Onita, Ji et al. 2002) of 67 cases which found an association of HIF2cc 
with a worse prognosis and necrosis. One possible explanation is that 
macrophages express HIF2cc in areas of inflammation as well as in 
perinecrotic areas. Inflammation in bladder cancer has been shown to be an 
independent marker of good prognosis in a study of 107 tumors (Offersen, 
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Knap et al. 2002). Possibly in this study by chance the HIF2a staining was 
more in inflarnmed tumors than necrotic ones. Another possibility is that 
these studies were inaccurate as tumors were staged by endoscopic 
resection only. Areas of comedo/microscopic gross/macroscopic necrosis as 
identified in this study were not distinguished in these other two papers. 
NIP3 is a cell death protein (Ray, Chen et al. 2000) regulated by HIF la 
(Sowter, Ratcliffe et al. 2001) that has been shown to cause necrosis rather 
than apoptosis. There was surprisingly no relationship found with necrosis 
suggesting the presence of necrosis in bladder cancer is not primarily driven 
by HIF upregualtion of NIP3 activity. Although there was a significant positive 
association with stage there was a significant inverse association with grade 
that is difficult to interpret. 
Angiogenesis is an independent prognostic factor on multivariate analysis for 
breast cancer (Fox, Leek et al. 1995) and lung cancer (Macchiarini, 
Fontanini et al. 1992) and prostate cancer (Jones and Fujiyama 1999). That 
angiogenic invasive tumors have a poorer prognosis does not imply that 
these tumors are well oxygenated. Microvessel counts are assessed at 
vessel hotspots. Between the hotspots there may still be significant areas of 
hypoxia and necrosis. High levels of angiogenesis correlated with high levels 
of necrosis in breast tumours and gliomas (Chan, Leung et al. 1998; Leek, 
Landers et al. 1999). The same may be true in bladder cancer. 
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This study found a high prevalence of gross necrosis in advanced bladder 
cancer (7% of Tl, 10% T2,16% of T3 and 25% of T4 turnours). Necrosis 
has been shown here to give prognostic information to tumours treated 
surgically. The presence of necrosis is also relevant to radiotherapy. For 
over fifty years (Gray, Conger et al. 1953) it has been known that the 
effectiveness of radiotherapy is directly proportional to tissue oxygen 
concentrations. Radiotherapy in bladder cancer is known to be more 
successful in lower stages (T2), where necrosis is less prevalent, and where 
a more complete endoscopic resection is performed before treatment, 
perhaps due to debridement of necrotic areas prior to treatment. 
The present study gives good evidence that gross necrosis and probably also 
comedo or microscopic necrosis is an independent prognostic factor in high- 
grade transitional cell carcinoma of the bladder. A more recent study of 
cystectomy specimens with more complete lymphadenectomies would be 
useful to see if presence of necrosis is still an independent prognostic factor 
when lymph node status is included in the statistical model. However this 
finding has potential use in prognosticating superficial high-grade bladder 
cancer after endoscopic resection (when no information on node status and 
limited information on stage is available) and hence selecting and counseling 
patients whether or not to have a radical cystectomy. Currently the presence 
or absence of necrosis is not part of any prognostic staging system, as it is 
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merely believed to be an epiphenomenon of higher stage tumours. These 
results also suggest that patients with necrosis in their turnours should be 
selected for trial of more intensive adjuvant therapies, both standard drugs 
and those targeting hypoxic cells. 
6.3.1 The clinical relevance of biomarkers and the structured analysis of 
biomarker studies 
TNM is the staging system used in bladder cancer to predict prognosis. On 
the basis of such staging patients will either be treated endoscopically '(with 
or without intravesical chemotherapy) or with radical cystectomy which 
carries major risks of mortality (3%) and morbidity (30%). The TNM staging 
system however is not accurate enough to predict which turnours will 
progress to metastasis and which will not. Hence for high risk superficial 
bladder cancer some patients could be safely spared a cystectomy, equally 
for invasive disease some patients could be selected for novel or alternative 
treatments if is was known that they would fail conventional treatment. For a 
long time mutations in p53 has been known to be one of the commonest 
mutations in cancer and mutated p53 occurs in 50% of invasive bladder 
cancers and carcinoma in situ. P53's physiological role at the GII/S 
checkpoint is to arrest the cell cycle or trigger apoptosis in conditions of 
cellular stress such as hypoxia or DNA damage. Hence mutation of p53 
would allow a cell to divide unchecked even in the adverse environment of a 
tumour. The great interest in p53 as a biomarker is indicated by the fact that 
at least 117 different studies of p53 in bladder cancer have been carried out. 
However a metanalysis of these studies concluded that there is insufficient 
evidence to use p53 as a prognostic marker in bladder cancer. Most if not all 
studies were retrospective. 70% of the studies contained less than 100 
patients, which is a minimum requirement for multivariate analysis. There 
was great heterogeneity in the laboratory and statistical methods used. The 
180 
method used to look for p53 mutation was the most convenient 
(immunohistochemistry) but not the most accurate, false negatives and 
positives occur. Secondly neoplastic change is a heterogenous and complex 
process involving many different pathways with many different molecules 
and it is perhaps nieve to expect a single molecule in a single pathway to 
add predictive value to all bladder cancers. However the authors 
acknowledged that there was sufficient evidence that p53 could have a role 
to play in bladder cancer management. However they recommended that a 
formal process of development of biomarkers be followed before introducing 
them into clinical practice, and that laboratory methods and statistical 
analysis should be centralized (Malats, Bustos et al. 2005). 
The National Cancer Institute has recommended a strategy for delineating 
the full development of biological determinants. (Cordon-Cardo 2004). The 
scheme follows a similar one as for drug trials: Phase I (pilot studies and 
assay development), Phase 11 (Retrospective clinical analysis) Phase III 
(Prospective confirmatory analysis) and Phase IV (Multi-institutional 
validation trials). Studies in bladder cancer are now proceeding down this 
path slowly A recent retrospective study of 191 bladder cancer patients 
qualifies as Phase 11 of the NCI strategy (Shariat, Karakiewicz et al. 2008). 
The study employed five related biomarkers (p53, pRB, p2l, p27, and cyclin 
El) and demonstrated a significant 11 % increase in predictive accuracy over 
predictive nomograms based on the TNM system alone. For cancer specific 
survival the presence of 4 or 5 altered biomarkers was a stronger predictor of 
death from bladder cancer than stage as indicated by their relative risks in 
multivariate analysis (RR1 2.5 for 4 or more biomarkers vs RR4.8 for stage T1 




Genearray experiments on normal human urothelial 
cells, peripheral blood monocytes and T-cells under 
hypoxia, and conclusion 
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7.1 Introduction 
In this chapter the in vitro hypoxia profile of genes upregulated in bladder 
cancer cell line EJ28 is compared with genearray profiles of hypoxia 
upregulated genes at 16 hours in normal human urothelial cells, peripheral 
blood monocytes and T-cells. These experiments were performed as single 
array experiments each. These experiments benefited from the increased 
array size and accuracy of Affymetrix arrays (HGU 133 A and B) which 
contain a total of 44,000 probes. 
There are no published papers on hypoxia upregulated genes in normal 
human urothelium, and having studied the hypoxia profile of cancer cell lines 
in culture, a natural comparison of interest would be normal human 
urothelium to see if there were any major differences. 
As demonstrated in Chapter Six of this thesis and observed by others HIF 2a 
has been located to tumour-associated macrophages in bladder cancer 
(Onita, Ji et al. 2002) and in tumour associated macrophages of many solid 
tumour types (Talks, Turley et al. 2000). As such the gene profile of 
monocytes to hypoxia is relevant to this thesis. A significant number of 
bladder cancers have areas of inflammation and coordinating the 
macrophage response are helper T-cells (CID4) typically in a Type IV cell 
mediated hypersensitivity reaction. Such a reaction may occur within bladder 
tumours naturally but also occurs when bladder tumours are treated with 
intravesical BCG (bacillus calmette-guerin), a commonly used treatment for 
high-risk superficial bladder cancer. Macrophages have also been proposed 
as a novel way of delivering gene therapy to areas of pathological hypoxia 
(Griffiths, Binley et al. 2000). HIF 2a has been shown in experiments 
exposing normal rats to hypoxia to be inducible by hypoxia in many normal 
tissues both parenchymal and non-parenchymal, and its role seems to be 
complementary to that of HIF 1 cc (Wiesener, Jurgensen et al. 2003). 
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Normal human urothelial cells were extracted and grown in culture by the 
author, human peripheral blood monocytes and CD4 T-cells were cultured, 
purified and T-cells were activated by addition of CD3/CD28 beads by 
Patrick Maxwell's laboratory (see Chapter 2). 
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7.2 Results 
The results displayed in Table 7.1 compare genes upregulated by hypoxia at 
16 and 24 hours in bladder cancer cell line EJ28 on the Sanger array to 
genes upregulated by hypoxia at 16 hours in 3 non-transformed cell types 
analysed on Affymetrix arrays. (see also Appendix 11-VI of this thesis for the 
actual lists of genes). 
Table 7.1 (On the next two pages) Genes upregulated by hypoxia at 16 
hours in cultured normal urothelium, peripheral blood monocytes and T-cells 
compared to the original 32 genes identified as hypoxia regulable in bladder 
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Figure 7.1 Graphic representation of 333 genes upregulated by hypoxia 
in activated T cells. A single vertical line represents each gene; intensity 
of red colour indicates fold upregualtion (most intense red =8 fold 
upregualtion, yellow = no fold change). In both (A) and (B) genes are 
ranked by fold upregulation of activated T-cells in hypoxia (B). 
(A) With unactivated normoxic levels as reference. Pure activation of 
T-cells in normoxia upregulates many more genes than the effect 
of pure hypoxia on unactivated T-cells. Without activation only 
relatively few genes are upregulated by hypoxia (12 genes in red 
on the left). Activating T-cells in normoxia upregulates many 
genes(333). 
(B) With activated normoxic levels as reference, this figure illustrates 
that once activated, all of the 333 activated genes also acquired 
the property of being hypoxia inducible >2 fold. 
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7.3 Discussion 
Many genes that are hypoxia regulable in the transformed bladder cancer 
cell line EJ28 were also hypoxia regulable in normal urothelia. A direct 
comparison is difficult as two different array types were used (Affymetrix 
for normal urothelium, Sanger array for EJ28) and not all genes on the 
Affymetrix array were present on the smaller Sanger array. However it 
can be clearly seen (Table 7.1) that at 16 hours of hypoxia the majority of 
the more strongly inducible genes in the upper half of the table have been 
induced in both EJ28 and normal urothelium suggesting that 
untransformed urothelial cells upregulate similar genes in hypoxia to their 
transformed counterparts. 
Several genes of interest were noted to be upregulated in normal human 
urothelium on the Affymetrix array but probes for these genes were not 
present on the Sanger array. Some are known to be hypoxia regulable 
such as p53 protein and carbonic anhydrase IX and stanniocalcin 1; 
fibroblast growth factor 11 was not previously reported. Stanniocalcin 1 is 
a calcium homeostasis protein upregulated in many tumour cell lines by 
hypoxia and hence is probably also upregulated in bladder cancer cell 
lines (Yeung, Lai et al. 2005). It also is known to play a likely 
physiological role, dependent on cytokine interleukin 6 (IL-6), in 
protection against ischaemia in untransformed cells in the brain and heart 
(Westberg, Serlachius et al. 2007) (Westberg, Serlachius et al. 2007). Of 
particular interest is the unreported hypoxic upregulation of fibroblast 
growth factor 11. Recently activating mutations in the FGF receptor 3 
(FGFR3) has been found to be present in the majority of stage Ta low- 
grade superficial bladder cancers. The same mutations in FGFR3 have 
been described in developmental disorders of human cartilaginous 
growth plates (e. g. ahcondroplasia, hypochondroplasia) (van Rhijn, 
Lurkin et al. 2001; van Rhijn, van Tilborg et al. 2002). Interestingly the 
cartilaginous growth plate is one avascular area where HIF has been 
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shown to be essential for development, in a cartilage-specific HIF1 knock- 
out mouse (Schipani, Ryan et al. 2001). 
The gene most upregulated by hypoxia (22-fold) in peripheral blood 
leucocytes was interleukin-1 (IL-1) which is the archetypal 
proinflarnmatory cytokine. Tumour necrosis factor (TNF) receptor and 
converting enzyme (2.5 and 2 fold, see appendix 111), another 
proinflammatory cytokine was also upregulated. These two genes are 
known to work synergistically in the inflammatory response whether 
induced by an infection, trauma, ischaernia, immune-activated T cells, or 
toxins (Warrell 2004). Unlike IL-1 , TNF induces cell death, particularly in 
tumour cells. TNF has been injected as part of anticancer protocols, 
either systemically or regionally, in order to bring about death of tumour 
cells. Similar to the effects of IL-1 in humans, TNF induces fever, 
headaches, myalgias, nausea, vomiting, and profound hypotension. 
Similar to IL-1 administration, elevated levels of IL-6, other cytokines, 
soluble cytokine receptors, and acute phase proteins are observed. In 
fact, the systemic responses to TNF and IL-1 are mostly 
indistinguishable. However, activation of the coagulation pathways is 
observed with TNF but not IL-1. In human subjects, TNF induces a short- 
term increase in circulating plasminogen activator activity with rises in the 
antigenic levels of urokinase-type plasminogen activator, a gene which 
transcript was also upregulated 2 fold on this array. Hence in monocytes 
we see a cluster of functionally related genes all being hypoxia regulable, 
turning on an inflammatory response to ischaemia. 
Comparing the untransformed cell types of normal human urothelium and 
peripheral blood monocytes which were both studied on the larger 
Affymetrix array, less than 7% (15 genes) of hypoxia upregulated genes 
were in common between the two cell types. This suggests that there can 
be a significant difference in the hypoxic response between different cell 
types. 
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Unactivated CD4 T-cells upregulate only a few genes under hypoxia, but 
when activated by the influence of CD3/CD28 activation, all the genes 
that were activated by CD3/CD28 also then became hypoxia regulable. 
This suggests that even within a single cell type other molecular 
pathways and the immune environment of the cell may have a dramatic 
effect on the scale and specificity of the transcriptional response to 
hypoxia. 
Some genes (highlighted in yellow in Table 7.1) were upregulated by 
hypoxia in all cell types. These mostly related to glycolysis but NIP3 
upregualtion was also common to all cell types examined. 
SLC16A3 the lactate transporter has already been delt with in Chapter 3 
but at least here we see that the Affymetrix array result in this chapter (no 
upregulation in normal urothelium) agrees with the result of the real-time 
RT-PCR used in Chapter 3. 
This chapter truly reveals a much greater heterogeneity in hypoxia 
response pathways than previously recognised. Each cell type may have 
different functions under hypoxia to conserve or activate which will 
determine the profile, and the extent of hypoxia interaction with the 
microenvironment may be highly tissue specific. 
7.3 Conclusion 
Perhaps the most significant finding of this thesis is that necrosis is an 
independent prognostic risk factor in bladder cancer (Chapter 6). This is 
the first published report of this, but another large multivariate study in 
transitional cell carcinoma of the upper renal tract has come to the same 
conclusion and indeed produced very similar survival curves and hazard 
ratios. As have large multivariate studies of necrosis in renal cell 
carcinoma and sarcoma (see table 6.10 pp161). This supports the 
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hypothesis of this thesis that the development of chronic hypoxia within 
bladder cancer is itself not a mere epiphenomenon of tumour growth but 
is associated with biologically more aggressive disease, invasion and 
metastasis. 
New pathways of relevance to hypoxia in bladder cancer have been 
defined by comparing two microarray experiments; a set of 8 replicates of 
a cancer cell line exposed to hypoxia and a set of 39 tumours against a 
reference panel of a variety of cancer cell lines in normoxia. The eight 
genes that were significantly upregulated on both arrays (Chapter 4, 
figure 4.4). Validating this method of investigating bladder cancer was the 
discovery that VEGF was one of the 8 genes picked out from the 6000 
transcripts. VEGF is already known to be the key hypoxia regulable 
angiogenic factor in bladder cancer (Crew, O'Brien et al. 1999; Reiher, 
Ivanovich et al. 2001). The results of a few of the most upregulated 
transcripts on both arrays (e. g. IGFBP3, SLC16A3, RNAse 4 in Chapter 
3) were validated in cell lines and untransformed cells by realtime RT- 
PCR and by the finding of raised levels of IGFBP3 and Angiogenin in the 
urine of bladder cancer patients (Chapter 5). It would have been 
interesting to see if levels if IGFBP3 in the urine correlated with amount of 
necrosis in patients' tumours but without reviewing another 157 sets of 
slides this was not possible. However from Chapter 6 we discovered that 
necrosis becomes more common with invasive disease, suggesting a 
possible reason why levels of IGFBP3 were significantly higher in 
invasive bladder cancer patients than in superficial disease. The function 
of IGFBP3 in hypoxia whether stimulating or inhibiting the IGIF growth 
factor pathway is controversial and would require further experiments with 
inhibitory RNA (RNAi), blocking antibodies to IGFBP3 and addition of IGIF 
I and 11 to the cell lines. The lactate transporter SLC16A3 was a gene of 
particular interest as it was not upregulated by hypoxia in normal 
urothelial cells or peripheral blood monocytes but was upregulated in all 
cancer cell lines examined and most of all (64 fold) in cultured endothelial 
cells. This pattern of upregulation was unusual, IGFBP3 mRNA for 
example was upregulated by hypoxia in normal urothelium and 
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endothelial cells and more so in bladder cancer cell lines. Consistent with 
this lGFBP3 protein was found in much greater baseline and hypoxic 
concentrations in cell-line supernatant compared with endothelial cell 
supernatant (Chapter 5). Levels of the protein were measured at 48 and 
72 hours compared with the 16 and 24 hour measurements made on the 
arrays to see if protein levels were present after the rise in mRNA 
transcript. IGFBP3 may play a normal physiological role in the 
sequestration of IGF to the nucleus (via importin beta 3 also found to be 
upregulated in hypoxia on the array) promoting proliferation. This 
baseline level of lGFBP3 may be upregulated in bladder cancer cells and 
enhanced by hypoxia both in normal urothelium, endothelium and bladder 
cancer cells. 
lGFBP3 has recently been shown to have antiangiogenic and apoptotic 
properties in a human prostate cancer xenograft model. Tumour size and 
number of blood vessels was reduced. Antiangiogenic properties were 
confirmed in three other in vitro assays and were found to be IGF 
independent (Liu, Lee et al. 2007) 
Leek has recently shed light on the role of HIR in tumours by growing a 
HIP competent and incompetent cell line as tumour spheroids. (Leek, 
Stratford et al. 2005). Both spheroids developed central necrosis showing 
that HIR does not protect against that. Oxygenation and nutrition and 
acidity are normal at the outer surface of the tumour spheroid where it 
comes into contact with the medium. Like a tumour however there is an 
increasing gradient of hypoxia and nutrition poor environment towards the 
centre of the spheroid. The HIR competent cells grew into larger tumour 
spheroids from day 3 largely because in the intermediate zone between 
rim and necrotic centre HIR protected the cells against apoptosis by 
inducing cell cycle arrest. The HIF incompetent cell line by comparison 
had higher apoptotic indices in this area. Hence the role of HIF 1 appears 
as stated in the introduction to be important to survival of cells (cancerous 
or normal cells) in conditions of cellular stress. Hence it is believed that 
inhibiting HIR in cancer could make cells more susceptible to apoptosis 
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from chemotherapy by preventing cell cycle arrest under conditions of 
cellular stress. 
It has subsequently been shown after work on this thesis was completed 
that very low oxygen tensions of 0.01% i. e. anoxia are required to cause 
apoptosis and this anoxic cell death occurs independent of any HIF1 
pathway such as NIP3. Oxygen tensions of 0.5% do not kill human 
tumour cells. (Papandreou, Krishna et al. 2005). 
In Chapter 4 individual fold changes and combined fold changes of 
transcripts on the in vivo microarray of these eight hypoxia inducible 
genes were found not to show a close correlation with microscopic or 
gross tumour necrosis or hypoxia-associated marker CA IX Only GLUT-1 
fold changes on the in vivo array showed a correlation with CA IX scores. 
Unfortunately CA IX itself was not on the Sanger array. This suggests 
that attempting to define a hypoxia profile for individual tumours based on 
a microarray analysis is not as simple as it seems at first. There are 
multiple possible reasons for this: Firstly the heterogeneity within a 
tumour is large with well vascularised areas and necrotic areas coexisting 
in many turnours. There are multiple cell types found in tumours, whether 
stroma or normal epithelium or neoplastic cells or inflammatory cells. 
Bladder cancers are thought to be oligoclonal so not all neoplastic cells 
will share a similar array profile. Cancers from different individuals and 
from different stages may have significantly different profiles. Some 
hypoxia inducible genes are controlled mostly at the protein level; 
HIFlafor example oxygen-dependent regulation is at the level of the 
protein rather than at transcript level. Finally this study relied on the 
Sanger array that is not as semi quantitative as the Affymetrix array, and 
requires a comparator reference RNA. The selection of the comparator 
reference RNA has to be carefully considered. 
In Chapter 5 an attempt was made to discover a microarray hypoxia 
profile for necrotic/hypoxic tumours by firstly grouping turnours by 
necrosis or CAIX staining and then performing multiple Mests across all 
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the thousands of transcripts on the array. However even with 32 turnours 
to analyze there were not enough replicates to allow for a statistically 
significant result. Simple Mests for each transcript produced significant 
results but this method requires sophisticated statistical analysis to 
correct for the use of multiple Mests. If such a study were performed 
again more replicates would be required of bladder cancers of a similar 
stage, perhaps with several samples from the same individual, with the 
amount of necrosis on histology carefully documented, and perhaps the 
selection of tissue used for analysis performed by laser microdissection. 
The finding in Chapter 6 that necrotic turnours have an independently 
poorer prognosis is an intriguing one. Chapter 5 provided some evidence 
that an untransformed cell line dies more readily in hypoxia than a cancer 
cell line, suggesting that perhaps one reason tumours with necrosis are 
more aggressive could be that in these tumours the chronically hypoxic 
environment has selected out cancer cells which can survive the adverse 
environment and that such cancer cells have a more aggressive 
phenotype. The selection out of p53 mutations by hypoxia in vitro 
(Graeber, Osmanian et al. 1996) and the recent finding that the 
HlFl(y+/p53+ immunohistochemical phenotype is independently 
associated with an adverse prognosis in bladder cancer 
(Theodoropoulos, Lazaris et al. 2005) fits with this hypothesis. It would be 
interesting to see if p53+ is associated with necrosis in bladder cancer. 
There are no studies on this to date. Levels of apoptosis and P53 on its 
own however have not proved consistent or independent predictors of 
prognosis in bladder cancer. 
Chapter 7 used purely Affymetrix microarrays to look at the heterogeneity 
in the hypoxic response of specific cell types (normal human urothelium 
in culture, normal human monocytes, normal human purified CD4+ Tcells 
activated and unactivated). The Affymetrix arrays used were larger and 
more precise than the Sanger arrays however a limited comparison was 
made with the Sanger array data from Chapter 3. Most genes that were 
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hypoxia regulable in the transformed bladder cancer cell line EJ28 on the 
Sanger array were also hypoxia regulable in normal urothelia. The 
Affymetrix array also identified p53 protein, carbonic anhydrase IX, 
stanniocalcin 1 (previously known to be hypoxia regulable in cancer) but 
also fibroblast growth factor 11 previously not known to be hypoxia 
regulable but of particular interest in bladder cancer superficial disease 
given the common mutation of FGFR3 recently discovered in superficial 
disease. Analysis and comparison of the other cell lines revealed a much 
greater heterogeneity in hypoxia response pathways than previously 
recognised. Each cell type may have different functions under hypoxia to 
conserve or activate which will determine the profile, and the extent of 




Purity of total RNA (tRNA) used in array 
experiments 
Figure A1.1 Purity of tRNA extracted from EJ28 biological replicates 
grown in normoxia (3 samples on left) and hypoxia (five samples on 
right). Agarose gel 1% with ethidium bromide, lug of RNA loaded in each 
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A study on carbonic anhydrase IX staining in 
superficial bladder cancer 
49 stage pTa to pT1 bladder cancers resected at TURBT were stained 
and scored for the hypoxia marker carbonic anhydrase IX. Intensity was 
scored from 0 to 3 (intense) and the percentage of tumour cells staining 
was also estimated to the nearest 10%. Scoring was performed 
separately for membrane staining and cytoplasm staining. Groups were 
split according to the median score. Although the study was under- 
powered there was a trend for tumours with more intense cytoplasm 
staining to have a worse prognosis, whereas membrane staining 
(although it is more striking) showed no significant adverse prognosis. 

















Total 25 24 
Table AVIA Carbonic anhydrase IX cytoplasm staining in 49 Ta-T1 
bladder turnours. There was no association with stage or grade 
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- -CA IX cytoplasm negabve 
n=24 
CA IX cytoplasm positive 
n=25 
p=0.076 log rank test 
Graph AVI. 1 Progression-free survival (defined as an increase in T 
stage) over 40 months of follow-up. There was a trend to worse 
prognosis in the CA IX staining group 
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-J- CA IX membrane positive 
n=25 
CA IX membrane negative 
n=25 
p=0.75 log rank test 
Graph AVI. 2 Membrane staining for CA IX showed no relationship or 
trend with time to first recurrence or prognosis 
--J-CA IX negative membrane staining 
n=25 
CA IX positive membrane staining 
n=25 
p=0.56 log rank test 
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